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Résumé
Les thérapies antirétrovirales actives (YAA) ont significativement amélioré
l’espérance de vie des personnes séropositives. Ces combinaisons de médicaments
requièrent une adhésion minimale de 95% de doses prises telles que prescrites pour avoir
un impact virologique optimal et éviter le développement de résistance aux médicaments.
En raison de leur complexité et des nombreux effets secondaires encourus par les TAA.,
l’adhésion à ces combinaisons de médicaments est souvent sous optimale. Il est donc
essentiel de mieux comprendre les facteurs associés à l’adhésion aux TAA, compte tenu des
implications sérieuses d’une adhésion sous optimale quant au traitement des individus
séropositifs et quant à la santé publique.
Cette thèse se compose de deux articles qui étudient les facteurs associés à
l’adhésion aux TAA chez des individus séropositifs (N = 82). Le premier article étudie
l’association entre l’adhésion sous optimale mesurée sur une période de 180 jours et les
caractéristiques suivantes : (1) certaines caractéristiques démographiques, (2) certaines
caractéristiques médicales, (3) certaines caractéristiques psychosociales, (4) croyances
associées à l’efficacité des médicanents. Cet article explore aussi l’association entre les
croyances associées à l’efficacité des médicaments et les caractéristiques des participants.
Le deuxième article décrit d’une part, les raisons sous-jacentes à l’omission de doses de
médicaments (barrières à l’adhésion) au moment d’adhésion le plus difficile; et d’autre part
les stratégies et les motivations qui facilitent généralement l’adhésion aux médicaments
(facilitateurs de l’adhésion) rapportées à un seul temps sur une période d’un an. finalement,
cet article explore aussi l’association entre l’adhésion aux TAA mesurée sur une période
d’un an et le nombre ou le type de facilitateurs de l’adhésion rapportés par les participants.
Dans le premier article, les résultats de la régression logistique indiquent que les
participants qui ont un problème d’alcool, un problème de drogue ou qui sont plus
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sceptiques par rapport à l’efficacité des TAA présentent un risque plus élevé d’adhésion
sous optimale. Les résultats indiquent aussi que les croyances quant à l’efficacité des TAA
sont associées au nombre de symptômes médicaux rapportés et au stade de la maladie.
Les résultats du deuxième article indiquent que les raisons les plus fréquemment
mentionnées au moment d’adhésion le plus difficile sont souvent reliées à des changements
de routine quotidienne. Les catégories principales de facilitateurs de l’adhésion rapportées
sont : (1) habiletés de planification; (2) perception positive des médicaments; (3) soutien
social; (4) motivation interne/engagement; (5) « seif-care ». L’adhésion mesurée sur une
période d’un an ne semble pas être reliée au nombre ou au type de facilitatetws mentionnés.
Les résultats de ces deux articles démontrent la complexité de l’adhésion aux TAA
puisque de multiples facteurs semblent l’influencer. Ces résultats mettent aussi l’emphase
sur l’importance: (I) de dépister les problèmes d’alcool et de drogue, (2) d’explorer les
croyances des patients envers leurs médicaments. Finalement, cette étude démontre qu’il
peut être intéressant de questionner les patients au sujet des facteurs qui facilitent leur
adhésion aux TAA plutôt que de se renseigner uniquement sur les barrières et les obstacles
à leur adhésion aux traitements.
Mots-clés : VIH, SIDA, adhésion, facteurs psychologiques, dépression, symptômes
médicaux, croyances, médicaments, drogue, alcool.
VAbstract
The advent of Highly Active Antiretroviral Therapy (HAARY) lias significantly
improved the life expectancy of HIV-infccted individuals. However, a strict threshold of up
to 95% of doses taken as prescribed ïs required for optimal virologic outcomes and to avoid
the development of resistance to medication. However, adherence to these regimens is often
suboptimal because they are frequently accompanied by side effects and are among the
most complex medication regimens to follow. Because suboptimal adherence has serious
implications for the treatment of HIV-infected individuals, as well as for public health, it is
critical to get a better understanding of factors associated with adherence to FLAART
regimens.
This dissertation consists of two articles designed to improve the understanding of
factors associated with HAART adherence in a sample of HIV-infected individuals ÇN =
82). The first article examined the relation between suboptimal adherence, measured over a
period of $0 days, and the following risk factors measured within 60 days ofbaseline: (1)
demographic characteristics, (2) medicaÏ characteristics, (3) psychosocial characteristics,
and (4) beliefs about medication efficacy. It also explored participants’ factors associated
with beliefs about medication efficacy. The second article explored both the reasons for
suboptimal adherence (barriers of adherence) reported at the worst adherence episode, and
the strategies and motivators that facilitated adherencc (facilitators of adherence) reported
at one time point over the course of one year. It also examined the relation between
participants adherence status measured over a one year period and the number or the type
of facilitators reported by participants.
In the first article, resuits of a logistic regression indicated that participants who had
an alcohol use problem, a drug use problem, or who were more sceptical about HAART
efficacy were at increased risk for suboptimal adherence. Results also suggested that beliefs
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about medication efficacy were associated with HIV-related medical characteristics, such
as number of medical symptoms and CDC disease stage.
Resuits of the second article indicated that the reasons most commonly mentioned
for missed medication doses at the worst adherence episode were interferences with daily
routine. Main categories of facilitators of adherence reported by participants werc: (1)
planning skills; (2) positive perception of medication; (3) social support; (4) commitment /
internai motivation; and (5) seif-care. The number and types of facilitators mentioned were
not associated with participants’ adherence status measurcd over a I -year period.
Resuits of these two articles highlighted the complexity of adherence by
demonstrating that adherence is influenced by multiple factors that tend to vary between
individuals. It also emphasized the importance of screening for problems with alcohol use
or drug use, and of inquiring about patients’ perceptions oftheir medication. These findings
also higfflighted the importance of asking patients about facilitators of adherence rather
than focusing uniqueiy on barriers or obstacles to adherence.
Keywords HIV, AIDS, medication adherence, psychological factors, depression. medical
symptoms, beliefs, expectations, drug, alcohol.
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Introduction
In North Arnerica, an estimated 790 000 to 1.2 million of people are living with the
Human Immunodeficiency Virus (HIV) or the Acquired Immtmodeficiency Syndrome
(AIDS). Approximately 52 000 (5 %) ofthese individuals live in Canada, and the number
of infected individuals has been rising at a rate of 12 percent since 1999 (SantéCanada,
2004). A large proportion of these individuals will eventually take or are already taking a
combination of medication to delay I-11V progression. The advent of Highly Active
Antiretroviral Therapy (HAART: usually defined as a Protease Inhibitor or a Non
Nucleoside Reverse Transcriptase Inhibitor combined with at least two other antiretroviral
drugs) has greatly improved the life expectancy and the quality of life of HIV-infected
individuals. However, HAART combinations generally require strict adherence behaviour:
flot only an adherence tbreshold of 95% or more of medication doses taken as prescribed,
but also consistency in this high rate of adhcrence over time. Ibis is crucial to achievc
optimal virologic outcomes and to avoid the development of drug resistance (Mannheimer,
Friedland, Matts, Child, & Chesney, 2002; Paterson et al., 2000). Because suboptimal
adherence has serious implications for the treatment of HIV-infected individuals and for
public health, it is critical to gain a better understanding of the factors that may be
associated with adherence behaviours.
The main objective of the present dissertation is to improve our understanding of
factors that influence adherence behaviours. Ibis dissertation consists of two articles: the
first article uses a quantitative approach to study specific risk factors for suboptimal
7HAART adherence, while the second article adopts a qualitative approach to explore both
the barriers to and the facilitators of HAART adherence.
In order to introduce this dissertation, the term “adherence” will first be defined in
the context of HIV-infection by briefly describing the impact of HAART on HW-infected
individuals’ health. The difficulties inherent to these treatment regimens including the
challenges associated with suboptimal adherence rates will also be exposed. Secondly,
mcthodological difficulties in adherence measurements will be reviewed, and the measure
of adherence used in the present dissertation wilJ be explained. Thirdly, a general review of
the literature on factors associated with adherence will be briefly presented. fourthly, the
general aim of this dissertation, as well as the specific goals, variables studied and
hypotheses of each article will be presented. Lastly, the methodology used will be briefly
explained.
1. Adherence in the context of HIVinfection
Since their aUvent, HAART regimens have been associated with reduced viral
replication, improved immunity, and decrcased risk of contracting opportunistic infections.
These drug treatments have also Uelayed 11W progression, and decreased the ftequency of
hospitalizations and deaths due to 111V (Altice & Friediand, 199$; Carpenter et al., 2000;
Chun & fauci. 1999; Deeks, Smith, Holodniy, & Kahn, 1997; Karon, fleming, $teketee, &
De Cock, 2001; Paul, Gilbert, Ziecheck, Jacobs, & Sepkowitz, 1999). Despite the important
advantagcs in taking HAART medication, reported rates of adherence are ofien suboptimal
3and at least a quarter of patients report that they skipped medication doses over the last few
days or the last week (Ammassari et al., 2001; Catz, Kelly, Bogart, Benotsch, & McAuliffe,
2000; Chesney, lckovics et al., 2000; Gifford et al., 2000; Nieuwkerk et al., 2001;
Schônnesson, Ross, & WilÏiams, 2004; Sethi, Celentano, Gange, Moore, & Gallant, 2003).
Indeed, adherence to HAARY is complicated by the fact that these regimens are often very
complex: individuals need to regularly take a large quantity of medication on a tight and
regimented schedule, with special requirements associated with each type of medication
taken (e.g., dietary restrictions). These regimdns also have numerous side effects and
require strict adherence behaviour over a long-term basis to be effective.
Mild adverse effects. including gastrointestinal problems such as nausea, diarrhea
and bloating, occur ftequently at initiation of treatment, and in some cases persist
throughout treatment. Other common side effects such as fatigue and headaches can occur
on a regular basis while on treatment (Montessori, Press, Harris, Akagi, & Montaner,
2004). furthermore, there are growing concerns about the long-term impact of these
regimens on HIV-infected individuals’ health and body image. Specifically, long-term
utilization of these drugs has been associated with metabolic disorders such as
lipodystrophy (abnormal fat redistribution) and hyperlipïdemia (elevation of lipids in the
bloodstream) (Armstrong, Calabrese, & Taege, 2002; Boyle, 2003; Montessori et al., 2004;
Steinhart & Emons, 2004).
In order to be effective and to avoid development of resistance to medication,
HAART combinations generally require an elevated adherence threshold as well as
4consistency in adherence over time. Suboptimal levels of medication exposures may permit
viral replication in the presence of medication leading to the emergcnce of drug-resistant
viruses (Clavel & Hance, 2004; Condra, Miller, Hazuda, & Emini, 2002). Patients with
suboptimal adherence may then be confronted with therapeutic failure andlor the risk of
transmitting a resistant strain of the virus to someone else. Levels of adhcrence have been
associated with virologie outcomes and CD4 lymphocyte counts in several smdies
(Bangsberg et al., 2000; Bangsberg, Perry et al., 2001; Duong et al., 2001; Mannheimer et
al., 2002; Pemo et al., 2002), but the number of missed doses of medication that could lead
to virological failure is unelear at this point (Deeks, 2003). However, the current recognized
threshold of adherence for optimal virologie outcome is 95% of doses taken as prescribed.
This is based on the results of a prospective observational study using Medication Event
Monitoring System (MEMS caps) to measure the adherence level of 99 HW-infected
individuals taking a medication regimen containing a protease inhibitor. This study found
that patients with 95% or greater adherence to their regimen had beller virologie outcome,
greater increase in CD4 lymphocyte counts, and lower hospitalization rates than those with
less than 95% adherence (Paterson et al., 2000). Therefore, even small differences in levels
of adherence were associated with significant differences in virologie outcome.
Consistency of adherence over time is also another cntïcal component because
patients who are generally highiy adherent but who miss their medication on a few
occasions have been found to develop more resistance to medieation than patients who are
consistently adherent to their regimen (Bangsberg et al., 2000; Perno et al., 2002; Walsh,
Pozniak, Nelson, Mandalia, & Gazzard, 2002). A study on long-term antiretroviral
adherence pattems based on 2 randomized control trials foilowed patients on a variety of
medication combinations over a I -year period, colÏecting data every 4 months
(Mannheimer et al., 2002). Their outcome measure was whether or flot 100% adherence
was reportcd at ail of the four visits. Participants who were consistently 100% adherent to
their regimen at ail visits were significantly more likely to achieve suppression of the virus
to an undetectable level, in comparison with others who were less consistent in their
adherence. In fact, 72% of the participants who reported being 100% adherent at ail four
visits had an undetectable viral load, compared to 66% of the participants who reported
being 100% adherent at only three visits. The percentage of individuals with an
undetectable viral load gradually decreased to 41%, 35% and 13% for participants who
reported respectively 100% adherence to two, one or zero of the follow-up visits.
Therefore, because incomplete adherence is associated with disease progression, full
medication adherence is currently considered a critical determinant of patient survival
(Garcia de Olalla et al., 2002; Wood et al., 2003). A prospective study that followed 1282
HIV-infected individuals who had been on their first antiretroviral combination therapy for
a mean period of 26.8 months confirmed this assumption. Participants who used
antiretroviral drugs intermittently, taking less than 75% of their medication in the first 12
months of the smdy, were 2.97 times more likely to die than participants who used
antiretroviral therapy more than 75% of the time afier controlling for other factors affecting
medical prognostic (Hogg et al., 2002).
6Lastly, interruptions of treatment are ofien accompanied by resurgence of viral
replication and immunological decline witbin a few weeks, even after pcriods of prolonged
viral suppression (Blankson, Persaud, & Siliciano, 2002). Because antiretroviral drugs are
targeting viral replication, they are only effective against actively replicating viruses when
taken regularly, and these regimens might therefore necessitate lifelong adherence to
control viral replication.
In this context, the current challenge in this fleld of practice is to help HIV-infected
individuals better adhere to their prescribed treatment regimens.
I. Methodological difficulties in adherence measurement
There is currently no “gold standard” to measure adhcrence. Adherence assessment
is flot standardized, and relies mainly on estimates of adherence rates because it is not
easily feasible to obtain directly observable measures (Wu, Ammassari, & Antinori, 2002).
Different measures of adherence have been used in the literature including electronic
devices, biologie and laboratory markers, piil counts, pharmacy records, providers
assessment, patient self-reports, or a combination ofthese sources (Turner, 2002). There arc
advantages and limitations associated with each of these measures. Electronic devices such
as Medication Events Monitoring Systems (MEMS; Aprex Corporation), that memorize
every time pu! botties were opened, are considered to be the most accurate tools to measure
adherence. However, these devices are ofien expensive and inconvenient to use for
participants because of their large size. Further, flot only is it impossible to be certain that
7the medication was taken when the boUle was opened, these devïces may underestimate
adherence if participants remove more than one pili at a time from the piilbox. Biologic and
laboratory markers are also considered to be relatively accurate measures of adherence
because they provide plasma drug levels. However, they can only provide an adherence
measuse for the previous 24 hours, and are difficuÏt to implement in clinical research. Pili
counts and pharmacy records are sometimes uscd but they are ofien perceived as intrusive
by patients, and it is flot possible to know with certainty if patients actually took their
medication. Furthcrmore, providers’ assessments of patients’ adherence has been shown to
be very inaccurate (Bangsberg, Hecht et al., 2001). Self-reported adherence is thc most
commonly used method to measure adherence. Even if self-reports could be influenced by
social desirability and usually tend to overestimate rates of adherence when compared to
more objective measures such as electronic devices (Liu et al., 2001), they have generally
been found to have a good correlation with other measures of adherence (Deeks, 2000;
Duong et al., 2001; Hugen et al., 2002) and have also been shown to predict therapeutic
outcome, as measured by HIV RNA level and CD4+ celi count (Manuheimer et al., 2002;
Walsh, Mandalia, & Gazzard, 2002). The optimal time frame to obtain an accurate self-
report of adherence is unclear, but a recent study (Godin, Gagne, & Naccache, 2003)
obtained a more adequate measure while using a 7-day period compared to a 2-day or a 30-
day period, when using increased viral Ïoad assays over 6 months as the validity criterion
for determining accuracy of measurement.
82.1 Adherence measurement for this dissertation
for thïs dissertation, it was originally planned to use self-reported questionnaires
with ail participants, and to implement MEMS with a subgroup of participants to validate
the self-reported measures. However, it was not possible to implement the use of MEMS
because most participants refused to use them, therefore only a self-reported adherence
measure using a time frame of 7 days was coilected.
A missed dose was defincd as omitting an entire scheduled dose of one medication.
The number of missed doses for each day was calculated by subtracting the number of
doses actually taken from the number of doses each participant was expected to take. These
missed doses were then added for the 7 day-period covcrcd by the questionnaire and
divided by the number of doses the participant was expected to take during that same
period of time. This resuh was finally multiplied by 100 to provide a percentage of
suboptimal adherence to the prescribed regimen. Individuals were categorized by adherence
status (adherence vs. suboptimal adherence) using the generally accepted 95% threshold of
adherence discussed above.
3, Factors associatcd with HIV medïcatïon adherence
More than 200 different factors have been associated, more or less consistently,
with adherence to treatments in various diseases (Meichenbaum & Turk, 1987). factors
generaily associated with adherence to HIV medication have recently been grouped into
9four different categories (Boucher & Veilleux, 2002; Chesney, 2003; Lafeuillade, 2001):
(1) patient-related factors including variables such as demographic characteristics, mcdical
characteristics, psychosocial characteristics and patients’ belief system; (2) medication
related factors such as complexity of treatment, frequency of dosing, etc.; (3) quality of the
doctor-patient relationship and general social support; and (4) general system of care.
However, despite a considerable amount of research to date, it is stiit difficuit to
accuratcly identify which group of individuals is most at risk of suboptimal adherence
given the variability in resuits. These divergent resuits might be caused by the variability in
the population or thc HIV-medication regimens studied, in the adherence measurements,
and in the operationalization of the term “adherence”. While most studies have focused on
the proportion of missed medication doses, a few studies have also looked at accurate
timing of doses and capacity to follow dietary instructions. furthermore, studies have often
used various tbresholds to define adherence varying from 80% to 100% of medication
doses taken as prescribed.
Because suboptimal adherence has critical implications for the treatment of HIV
infected individuals, as well as for public health, it is important to continue to identify the
essential factors associated with suboptimal adherence. This knowledge will help to
develop and test interventions that target risk factors and behaviours.
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Given the large body of research availahie on adherence to HIV medication, the
oresent dissertation will limit its focus to factors that were examined in both articles
contained herein for their potential association with suboptimal adherence.
4. Goals of the dissertation
The aim of the present dissertation is to enhance the understanding of factors related
to adherence behaviours in a sample of 82 HIV-infected individuals by: (1) exploring risk
factors for suboptimal adherence in article 1, and (2) exploring both the barriers to
adherence (namely reasons for missed medication doses) and facilitators of adherence
(namely strategies and motivators that enhance adherence) in article 2.
4.1 Goals ofthe first article
The first article aimed to identify risk factors that might predict suboptimal
adherence measured subsequently over a 6-month period, and to explore the relationship
between beliefs about medication and different participants’ demographic, medical, and
psychosocial characteristics. The following risk factors for suboptimal adherence were
examined: (1) demographic characteristics: age, education; (2) HIV-related medical
characteristics: disease stage and number of medical symptoms reported; (3) psychosocial
characteristics: alcohol use problem, drug use problem, depressive symptoms, and (4)
beliefs about medication efficacy.
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4.11 Risk factors for subopfimal adherence to HAART studied
The risk factors for suboptimal adherence tested in the first article were selected to
reflect a general cognitive-behavioural approach to study adherence. Factors selected
included personal factors, emotional factors, and cognitions with the goal of predicting a
given behaviour: adherence to medication.
A. Dernographie variables
Demographic characteristics have generally been found to be poor predictors of
suboptimal adherence to medication (Rabkin & Chesney, 1999), but a few studies have
reported associations between adherence and age, as well as adherence and education or
socio-economic status. Some studies found that younger age was associated with a higher
likelihood of suboptimal adherence (Aloisï et al., 2002; Decker, Dezii, Burtcel, Kawabata,
& Hodder, 2002; Gordillo, de! Amo, Soriano, & Gonzalez-Lahoz, 1999; Moafti et al..
2000), while other studies found that younger age was associated with a !ower likelihood of
suboptimal adherence (Molassiotis et aI., 2002; Stone et al., 2001). Furthermore, some
studies did flot detect any association between age and suboptimal adherence (Hoizemer et
al., 1999; Mohammed et al., 2004). A lower education level or a lower socio-economic
status has been associated with suboptima! adherence in a few studies (Catz, Heckman,
Kochman, & DiMarco, 2001; Kleeberger et al., 2001).
12
B. Psychosocial variables.
a) Alcohol use problems
An alcohol use problem is defined as hazardous and harmful alcohol use that could
lead to alcohol dependence. Following the World Health Organization terminoÏogy
(Saunders, Aasland, Babor, de la Fuente, & Grant, 1993), hazardous consumption can be
defined as alcohol consumption that implies the risk of physical and I or psychological
harm; while harmfttl alcohol use can be defined as the presence of physical or
psychological complications. Alcohol use problem has been quite consistently associated
with an increased risk of suboptimal adherence in several studies (Aloisi et al., 2002;
Chesney, Ickovics et al., 2000; Lucas, Gebo, Chaisson, & Moore, 2002; Moatti et al., 2000;
Mohammed et al., 2004; Samet, Horton, Mcli, freedberg, & Palepu, 2004).
b) Drug use probems
A drug use problem is defined as the use of “recreational drugs” such as: (1) drugs
prescribed or “over the counter” drugs in excess of direction and (2) any non-medical use
of drugs within the past year, exciuding alcohol and tobacco (Skinner, 1982). It also reflccts
a drug consumption that interferes with different life domains of the individual. Current use
of injection or non injection dmgs has been quite consistently associated with suboptimal
adherence (Aloisi et aL, 2002; Bouhnik et al., 2002; Gordillo et al., 1999; Lucas, Cheever,
Chaisson, & Moore, 2001; Moaffi et al., 2000). However, former drug use is usually flot
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associated with suboptimal adherence (Hoizemer et al., 1999; Lucas et al., 2001), unless it
is associated with current social instability (Bouhnik et al., 2002).
c) Depressive symptoms
Depressive symptoms correspond to symptoms described in the diagnosis criteria of
depressive disorders in the American Psychiatrie Association’s Diagnostic and Statistical
Manual of Mental Disorders — Fourth Edietion (DSM-IV; 1994). Depression or depressive
symptoms have been associated with suboptimal adherence in several studies (Ammassari
et al., 2004; DiMatteo, Lepper, & Croghan, 2000; Gordillo et al., 1999; Holzemer et al.,
1999; Starace et al., 2002), but a few studies have also found the absence of such an
association (Stone et al., 2001).
C. HIV-related medical characteristics
a) Medical symptoms
Medical symptoms studied represent a combination of symptoms of HIV or
medication side effects commonly experienced by HIV-infected individuals. A greater
number of symptoms of H1V (Ammassari et al., 2001; Holzemer et al., 1999; Wagner,
2002) or side effects ofmedication (Ammassari et aL, 2001; Trotta et al., 2002) have been
associated with suboptimal adherence in several studies. In a recent study (Heath, Singer,
O’Shaughnessy, Montaner, & Hogg, 2002) subjects reporting at least one severe symptom
were found to be more than twice as likely to have suboptimal adherence. Furthermore,
gastrointestinal side effects such as nausea, vomiting and diarrhea, were usuaÏly the reasons
14
most ofien cited for discontinuation of medication (O’Brien, Clark, Besch, Myers, &
Kissinger, 2003).
b) Disease stage
Disease stage is defined based on the 1993 Classification system for HIV infection
from the Center for Disease Control (Castro et al., 1992). It reflects current standards of
medical care for HIV-infected individuals, and categorizes these individuals into 9 mutually
exclusive categories on the basis of clinical conditions associated with 111V infection and
CD4+ T-lymphocyte counts (sec Table I,p. 23). Individuals are classified based on CD4+
T-lymphocyte counts per microliter of blood into the following categories: (1) 500 cells/p.
L; (2) 200-499 cells/
‘
L; (3) < 200 cells/ t L; arid are concurrently classified into three
clinical categories: (1) to be classified into categoly A an individual needs to have one or
more of the following conditions: asymptomatic 111V infection, persistent generalized
lymphadenopathy, acute HIV infection with accompanying illness or history of acute 11W
infection; (2) to be classified into category B an individual nceds to have symptomatic
conditions that are flot included in category C (AIDS) and to meet at least one of the
following criteria: a) conditions arc attributed to HIV or b) conditions arc considered to
have a clinical course or to require management that is complicated by 111V infection (e.g.:
candidiasis, constitational symptoms such as fever or diarrhea lasting more than 1 month);
(3) to be classified into category C an indïvidual needs to have or have had at one point the
clinical conditions that are listed in the AIDS surveillance case definition (e.g.: Kaposi’s
sarcoma. Pneumocystis carinii pneumonia). These nine categories can be subdivided again
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into three categories: asymptomatic HW-infection, symptomatic HIV-infection, and AIDS
diagnosis. Individuals are considered asymptomatic if they are at the clinical stage A, and
have CD4+ counts of at least 200 cells/ t L. Individuals are considered symptomatic if they
are at the clinical stage B, and have CD4+ counts of at least 200 cells/ t L. AIDS is
diagnosed when individuals reach the clinical stage C or if they have CD4+ counts of less
than 200 cells/pL.
In one study (Gao, Nau, Rosenbluth, Scott, & Woodward, 2000) participants in
clinical stages B or C were more adherent to their medication than participants in stage A.
Another study noted a tendency of participants in the clinical stage C to be more adherent
to medication (Molassiotis et al., 2002). b our knowledge, no othcr study has supported
the association between suboptimal adherence and less severe disease stages.
D. Beliefs about medication effieacv
Beliefs about medication efficacy are dcfined as the perceived health benefits that
participants are expecting to gain from their HAART medication. It is also defined as the
perceived positive or negative impact on ftmctioning that participants are expecting to get
from their HÀART medication. A few studies in HIV have shown an association between
suboptimal adherence and less positive betiefs about medication, more negatïve
expectancies about the outcome of medication or more concems about the adverse effect of
medication (Aversa & Kimberlin, 1996; Home et al., 2004; Johnson, Catz et al., 2003;
Murphy, Roberts, Hoffman, Molina, & Lu, 2003; Remien et al., 2003; Roberts, 2000;
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Roberts & Mann, 2000; Siegel, Schrimshaw, & Dean, 1999). Littie is known about factors
that influence beliefs about medication efficacy. b our knowledge, only one study
(Reynolds et al., 2004) has explored factors associated with beliefs about medication and
found that: less positive beliefs about medication efficacy were associated with personal
and situational factors such as depression, stress, lower education level.
4.12 Factors tested in association with beliefs about medication efficacy
The following participants’ characteristics were explored in association with beliefs
about medication: (1) demographic characteristics: age, gender, education; (2) medical
characteristics: disease stage, number of medical symptoms due to illness or side effects of
medication, viral load (indicator of health status), hospitalization in the past 6 months; (3)
depressive symptoms.
4.13 Hypotheses ofthe first article
Based on resuits of prior studies cxposed above, it was hypothesized that a greater
number of medical symptoms, a greater number of depressive symptoms, less positive
beliefs about medication efficacy, alcohol use problem, and drug use problem would
predict suboptimal adherence to medication; while demographic characteristics and disease
stage would flot predict suboptimal adherence. Because of the lack of knowledge about
factors associated with more positive beliefs about medication efficacy, no specific
hypothesis was made about their association with participants’ characteristics.
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4.2 Goals of the second article
The second article had for objective to increase our understanding of adherence
behaviours by exploring and describing both the barriers to (namely reasons for suboptimal
adhercnce) and the facilitators of (namely strategies and motivators of adherence) HAART
adherence reported by HIV-infected individuals. The second goal was to explore the
association between number or type categories of facilitators used by participants and their
adherence status. Because this study was exploratory in nature, no specific hypothesis was
made.
4.21 Barriers and facilitators of adherence to HAART
Most studies on adherence behaviours have had their primary focus on obstacles or
barriers to adherence. In order to gain a more complete understanding of adherence
behaviours, the second article explores two complementary sides of the decision making
process as they were reported by HW-infected individuals: reasons for suboptimal
adherence (barriers) and strategies or motivators (facilitators) of adherence behaviours.
A. Barriers to adherence
Barriers to adherence are defined here as reasons reported by participants for
missing their medication doses. Severai quantitative studies have explored reasons for
suboptimal adherence in HW-infected individuals (Catz et al., 2001; Chesney, Ickovics et
aÏ., 2000; Chesney, Morin, & Sherr, 2000; DeMasi et al., 2001; Eldred, Wu, Chaisson, &
Moore, 199$; ferguson et al., 2002; Gifford et al., 2000; Kleeberger et al., 2001;
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Mannheimer et al., 2002; Molassiotis et ah, 2002; Reynolds et ah, 2004). The reason most
oflen cited across smdies was “forgetfiulncss” Other common reasons were: changes in
daily routine, interferences from social context such as: being too busy, being away from
home, eating a meal at a wrong time, sleeping tbrough a dose; and practical barriers such as
complexity of drug regimens, and number of medication to take. In this second article,
reasons for suboptimal adherence will be explored at participants’ worst time of adherence
within a one year period.
B. Facititators ofadherence
facilitators of adherence represent strategies or motivators that participants believed
generally helped them adhere to their medication regimens. b our knowledge, only two
studies have explored facilitators of adherence and resuits of these studies will be described
in greater details in the introduction ofthe second article.
5 Method
51 General design
Both studies included in this dissertation used a longitudinal design. However,
different time frames were used to measure adherence: the fiist article measured adherence
status over 120 days (6 months), while the second article measured adherence status over
360 days (about 1 year).
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To answer our research question, it was necessary to render individuals comparable
through time by organizing the adherence data into 12 fixed intervals of 30 days starting at
study entry for a total period of 360 days. However, this resulted in some participants flot
having at least one entry every 30 days. In order to insure that we had a reliable measure of
adherence behaviour, without detrimentally minimizing sample size, we required that at
least 3 measures of adherence out of 6 (article 1). or 6 measures out of 12 (article 2), be
available for a subject to be included in the analyses. for each 30-day interval, both the
average and the “worst” self-reported adherence percentage were calculated. Individuals
were categorized by adherence status (adhcrence vs. suboptimal adherence) using a 95%
threshold of adherence, usually accepted in the literature. Therefore, participants who
reported that they had taken less than 95% oftheir prescribed doses at least one time over a
period of 6-month (article 1) or one year (article 2) were considered to have suboptimal
adherence to their regimen.
5.12 Design used for article 1
The first article is a prospective longitudinal study that explores the association
between potential risk factors measured within 60 days of baseline. and adherence status
measured subsequently over a period of 180 days (6 months). It also explores cross
sectionnally the association between beliefs about medication efficacy and participants’
characteristics both measured within a 60-day period of baseline. Most risk factors were
measured wïthin a 60-day period ofbaseline. Both the average and the “worst” scores were
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retained for each factor. To measure alcohol and drug use problems ail scores available for
a period of one ycar were retained because these questionnaires probed retrospcctively
about alcohol and drug use problems within the past year. If more than one measure of
alcohol problem or drug problem was available, only the “worst” score was retained for the
analyses.
5.13 Design used for article 2
The second article is a descriptive, expioratory study. It uses a qualitative
methodology to describe the reasons most frequently mentioned by participants at the time
of their worst adherence level within a one-year period. It also describes categories of
adherence facilitators reported by HIV-infected individuaÏs at one specific time point.
Finally, it explores the potential association between the number or the types of categories
of facilitators mentioned, and participants’ adherence status measured subsequently over a
period of 360 days (one year).
Tt was not possible to control time of administration for the facilitators of adherence
questionnaire because it was administered only once, at different time intervals within a
period of 360 days of baseline. However, these facilitators should be relatively stable over a
period of severai months since participants in this study had been taking medication for a
few years and were asked what generally helped them adhere to their regimens. It can be
reasonably postulated that these individuals had already developed a set of habits and/or
strategies to facilitate adherence.
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5.2 Participants
One hundred and fine HIV-infected individuals undergoing HAART treatments
were approached for this study. A total of 27 participants were excluded from the analyses
based on specific criteria discussed firther in the two articles included in this dissertation.
The final sample was composed of 82 individuais of which 71 were men (86.6%) and 11
women (13.4%) with a mean age of 41 years (SD = 7.2; range 21-64) and education level
of 13.3 years (SD = 2.3; range 8-19). Differenccs between these $2 participants and
excluded subjects are discussed in more details in the articles.
5.3 Measures
Ail the measures used for this dissertation are presented in the two articles and are
also available in Appendix A. Table II (p. 24) summarizes the variables under study for
each article, and the instrument used to measure them.
5.4 Procedure
Participants were recmited in the Toronto Metro Area through community
organizations and Hospital Centers for a larger multidisciplinary research project on the
psychosocial. behavioural and treatment factors associated with adherence to HAART in
HIV-infection. The project included two distinct but linked studies: TNFORMM-HAART
Study used a natural history design in order to identify the main predictors of HAART
adherence over a period of time exceeding 12 months. The MAX-HAART Study
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compared the tolerability and feasibility of two distinct adherence-enhancing interventions
(solution-focused intervention and cognitive intervention) with a subgroup of HIV-infected
individuats who had been categorized as having adherence difficulties in the INfORMM
HAART study. Ail participants provided written informed consent to participate in this
research as approved by the St. Michael’s Hospital Research Ethics Board. Individuals who
gave informed consent and decided to participate in this research were scheduied for 14
regular 30 to 45 minutes visits over a period of one year to complete a variety of
behavioural, neuropsychological and psychosocial questionnaires and inventories.
Participants received remuneration for their participation in this study at the rate of 10$ to
20$ per hour depending on the type and scope of instruments administered.
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Table 1. 1993 CDC Revised Classification System for I-11V infection and AIDS surveillance
(adapted from Castro et al., 1992)
Clinical categories
Category (A) Category (B) Category (C)
Asymptornatic, Symptomatic. flot A AIDS-indicator
acute (prirnary) I—11V or C conditions conditions
or PGL*
(1) 500/pL Al BI Ci
(2) 200-499/pL A2 B2 C2
(3) <2OOpL A3 33 C3
* PGL = persistent generalized lymphadenopathv
** Asymptornatic stage: Al — A2
Symptornatic stage: Bi — B2
AIDS diagnosis: A3 — B3 — Cl — C2 — C3
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Table II. Variables of interest and measures used in the two articles ofthis dissertation.
Variable Measure Article(s) where this
variable appeared
Demographic information DEMO I and 2
Adherence Individualized Medical 1 and 2
Monitor (IMM)
Depressive symptoms Beck Depression Inventory
(BDI-II) — total score and
cognitive subscale
Medical symptoms Symptoms questionnaire 2:
SYM2 (21-item scale)
Beliefs about medication HEXP 1
(medication effect on health)
HEXP2
(positive or negative impact of
medication on functioning)
Reasons for missing medication Reasons questionnaire 2
(REASONS)
facilitators of adherence Adherence Fac ilitators 2
Questionnaire (ADHQ)
HIV-disease medical information NCOND I and 2
HCOND
Alcohol use problems Alcohol Use Disorders 1 and 2
Identification (AUDIT- calted
ALCO)
Drug use problems Drug Abuse Screening Test 1 and 2
(DAST-20 called DRUGS)
Chapter 1: Article 1
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Abstract
Ibis is a prospective longitudinal exploratory study examining risk factors associated with
subsequent suboptimal adherence to HAART over a 6-month period in a group of $2 HIV
infected individuals. Risk factors examined included: demographic characteristics, HIV
related medical characteristics, psychosocial fimctioning, and beliefs about medication
efficacy. This study also examined the correlates of beliefs about HAART medication.
Logistic regression analyses rcvealed that the presence of an alcohol use problem, a drug
use problem, and less positive beliefs about medication efficacy increased the risk of
suboptimal adherence. An exploration of beliefs about medication revealed an association
with HIV disease staging and with number of medical symptoms due to illness or side
effccts. Theoretical and clinical implications ofthese findings are discussed.
Key Words: Medication adherence — Antiretroviral therapy — HIV-infection —
Beliefs — Substance use problems
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Introduction
The advent of Highly Active Antiretroviral Therapy (HAART: usually defined as a
Protease Inhibitor (PI) or a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
combined with at least two other antiretroviral drugs) has greatly improved the life
expectancy of HIV-infected individuals. These medication regimens have been associated
with reduced viral load, improved immunity, decreased risk of getting opportunistic
infection, delayed HW progression, decreased hospitalizations frequency, and lower death
rates due to HIV (Altice & Friedland, 199$; Carpenter et al., 2000; Chun & Fauci, 1999;
Deeks et al., 1997; Karon et al., 2001; Paul et al., 1999). However, HAART combinations
generally require an adherence threshold of up to 95% of medication doses taken as
prescribed for optimal virologie outcomes and to avoid the development of drug resistance
(Paterson et al., 2000). Consistency of adherence is also another critical component of
therapeutic success because patients who miss taldng their medication on only a few
occasions, even those who are generally adherent, are more likely to develop resistance to
medication than patients who are aiways consistent in their adherence (Bangsberg et ah,
2000; Maimheimer et al., 2002; Perno et al., 2002; Walsh, Pozniak et al., 2002). The
challenge is that reported rates of adherence in HW-infected individuals are often
suboptimal. In fact, at least a quarter of patients report that they skipped medication doses
over the last few days (Ammassari et al., 2001; Catz et al., 2000; Chesney, Ickovics et al.,
2000; Gifford et al., 2000; Nieuwkerk et al., 2001; Schinnesson et al., 2004; Sethi et al.,
2003).
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Over the past decade, several factors that are associated with suboptimal
adherence to medication in HW and AIDS have been identified. These factors, which are
more or less consistently linked to suboptimal adherence, have been grouped into four
different categories (Boucher & Veilleux, 2002; Chesney, 2003; Stone, 2001): (1) patient
related factors; (2) medication-related factors; (3) doctor-patient relationship and other
social support; and (4) general system of care. However, despite a considerable amount of
research to date, it is stili difficuit to accurately identify which group of individuals is at the
most risk of suboptimal adherence given the variability in resuits. Because suboptimal
adherence has critical implications for the treatment of HW-infected individuals, as well as
for public health, il is important to continue to identify the essential factors associated with
suboptimal adherence in order to then deveîop and test interventions that target risk factors
and behaviours. The main objectives of the present study are: (1) to investigate individual
risk factors that are associated with subsequent suboptimal adherence over a 6-month
period in a sample of HIV-infected individuals; and (2) to explore the relationship between
beliefs about medication efficacy and demographic, medical, and psychosocial
characteristics. We predict the risk of suboptimal adherence to be associated with: a higher
number of medical symptoms duc to illness or side effects of medication; a higher number
of depressive symptoms; less positive beliefs about medication efficacy; and both alcohol
and drug use problems. Like most previous studies, we anticipate that demographic
variables and HW disease stage markers will not increase the risk of suboptimal adherence.
Due to the limited information available about the impact of both positive and negative
beliefs about medication efficacy on adherence behaviours, we do flot have specific
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hypotheses about their association with other characteristics. As such, our objective is to
gain a better understanding of these beliefs by exploring their associations with
demographic characteristics, HIV-related medical characteristics, and psychosocial
functioning.
For the present study. we focused on the following risk factors for suboptimal
adherence: (1) demographic characteristics such as age and education; (2) HIV-related
medical characteristics such as disease stage (CDC-93 stage of illness: asymptomatic,
symptomatic, or ATDS), and number of medical symptoms due to illness or side effects of
medication ; (3) psychosocial characteristics such as alcohol and drug use problems, and
depressive symptoms; and (4) patients’ beliefs about medication efficacy.
In terms of previous studies, demographic characteristics have usually been reported
as poor predictors of suboptimal adherence to medication (Rabkin & Chesney, 1999),
although there are a few studies that have linked suboptimal adherence to different age
groups (Becker et al., 2002; Gordillo et al., 1999; Molassiotis et al., 2002; Stone et al.,
2001), and to lower levels ofeducational achievement or lower socio-economic status (Catz
et al., 2001; Kleeberger et al., 2001).
Arnong HIV-related medical characteristics, HIV disease staging (asymptomatic,
symptomatic, AIDS) has been associated to adherence in only a few studies, with more
severely iii patients being more adherent, and perceiving a stronger relationship between
suboptimal adherence to medication and AIDS-related complications (Gao et al., 2000;
Molassiotis et al., 2002). In addition, likely due to the fact that 141V-infected individuals are
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ofien asymptomatic when starting their medication, there are consistent findings linking
a high frequency and/or intensity of medical symptoms or sidc effects while on medication
with suboptimal adherence to medication (Ammassari et al., 2001; Heath et al., 2002;
Hoizemer et al., 1993; Wagner, 2002).
Among psychosocial variables, the presence of depressive symptoms (Ammassari et
al., 2004; Catz et al., 2000; Gordillo et al., 1999; Starace et al., 2002), active illicit drug use
(Bouhnik et al., 2002; Lucas et al., 2001; Lucas et al., 2002; Moatti et al., 2000), and
alcohol use problems (Aloisi et al., 2002; Chesney, Ickovics et al., 2000; Lucas et al., 2002;
Moatti et al., 2000; Mohammed et al., 2004), have ofien been associated with an increased
risk of suboptimal adherence.
Although beliefs about medication were previously studied with psychiatric patients
and patients presenting chronic ilinesses (Home & Weinman, 1999; Ruscher, de Wit, &
Mazmanian, 1997), interest in patients’ beliefs about medication efficacy has only recently
been starting to emerge in the HIV literature. Studies (Aversa & Kimberlin, 1996; Johnson,
Catz et aI., 2003) have also shown that patients who have less positive expectancies about
the outcome of the medication treatment were more likely to have a suboptimal level of
adherence to medication. This was also confirmed by a recent study (Home et al., 2004)
which fotmd that adherence was lowest among people who had more concems about the
adverse effects of medication, especially when these concerns out weighted the perceived
necessity of taking the medication. Furthermore, several qualitative studies have found
similar resuits. Belief that the treatment is beneficial to health and survival was ofien
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mentioned as a facilitating factor for taking medication, and conversely, doubts about the
efficacy of the medication was ofien associated with more difficulty adhering to medication
regimen (Murphy et al., 2003; Remien et al., 2003; Roberts, 2000; Roberts & Mann, 2000;
Siegel et al., 1999).
Littie is known about factors that influence beliefs about medication efficacy. To
our knowledge, only one study (Reynoids et al., 2004) bas explored factors associated with
beliefs about medication. Ihis study found that less positive beliefs about medication
efficacy was associated with personai and situational factors such as depression, stress and
lower education level.
Method
Participants
One hundred and nine aduits with HTV-infection on HAÀRT treatment were
approached for this study. Twenty-seven participants of this sample (24.8%) couid flot be
inciuded in the final analyses: 14 (12.8%) dropped out and 13 (11.9%) were excluded for
eïther their inability to read and write English, inability to complete the questionnaires in a
reliable fashion, or because of alcohol or drug intoxication at the time of the baseline
interview. Comparisons between the excluded participants (N=27) and the final sample
(N=82), using chi-squares and t-tests analyses, showed that groups were comparable on ail
demographic characteristics, HW disease markers, and indicators of health status, except in
the case of monthly income and type of risk factor for HIV. Spccifically, participants
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excluded from the study generalÏy had a Ïower income (t (99.9) = 3.42, p .001) and
tended to report intravenous drug use as a risk factor for HIV more often than individuals in
the study sample (z2(l N=95) = 5.92, p = .025).
The final sample was composed of 82 individuals of whom 71 were men (86.6%)
and 11 women (13.4%) with a mean age of 41 years (SD = 7.2; range 21-64) and education
level of 13.3 years (SD = 2.3; range 8-19). $ee Table III (p. 67) for a description of
demographic and medical characteristics of participants.
Procedures
Participants were recruited, starting in the Spring of 2000, in the Toronto Metro
Area through cornmunity organizations and Hospital Centers for a larger multidisciplinary
research project on the psychosocial, behavioural and treatmcnt factors associated with
adherence to HAART in HIV-infection. The project included two distinct but linked
studies: INFORMM-HAART Study (Identification of Necessary Factors for Medication
Management of HAART) and MÀX-HAART Study (Maximizing HAART Adherence
Through Behavioural Interventions). The JNfORMM-HAART Study used a natural history
design in order to identify the main predictors of HAART adherence over a I 2-month
period of time. The MAX-HAART Study compared the tolerabïlity and feasibility of two
distinct adherence-enhancing interventions (solution-focused intervention and cognitive
intervention) with a subgroup of HIV-infected individuals who had been categorized as
having adherence difficulties during their participation in the INfORMM-HAART study.
Ail participants provided written informed consent to participate in this research as
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approved by the St. Michael’s Hospital Research Ethics Board. Individuals who gave
infonned consent and decided to participate in this research were scheduled for 14 regular
30 to 45 minutes visits over a period of one year to complete a variety of behavioural,
neuropsychological and psychosocial questionnaires and inventories. Participants received
remuneration for their participation in this study at the rate of $ 10-20 per hour depending
on the type and scope of instruments administered.
Design
The current study is a prospective longitudinal exploratory study looldng at
potential risk factors, measured within a 60-day period from baseline, that may predict
suboptimal adherence measured over a subsequent 180-day period (6 months). We used a
cross-sectional design approach to explore the association between beliefs about medication
efficacy and participants’ characteristics.
To answer our research question, it was necessary to render individuals comparable
through time by organizing the adherence data into 6 fixed intervals of 30 days starting at
study entry for a total period of 180 days. In order to insure that we had a reliable measure
of adherence behaviour, without detrimentally minimizing sample size, we required that at
least 3 measures of adherence out of 6 be available for a subject to be included in the
analyses. For each 30-day interval, both the average and the “worst” self-reported
adhcrencc percentage were calculated. Individuals were categorized by adherence status
(adherence vs. suboptimal adherence) using a 95% threshold of adherence (this threshold
was used because it is well accepted in the literature as the level to achieve the best
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virologie response). Therefore, participants who reported that they had missed more than
5% of their prcscribed doses at least one time over a period of 6-month were considered to
have a suboptimal adherence to HAART. Most predictors were measured within a 60-day
period of baseline. Both the average and the “worst” scores werc retained for each
predictor. To measure alcohol and drug use problems, ail scores available for a period of
one year were retained because these questionnaires probed retrospectively about alcohol
and drug use problems within the past year. If more than one measure of alcohol use
problem or drug use problem was available, only the “worst” score was retained for the
analyses.
Measu res
The following questionnaires were administered to each participant:
A general demographic questionnaire including questions such as gender, age,
education level, income. etc. vas administered at baseline.
A questionnaire about general and HIV-specific medical status, including questions
on prior opportunistic infections, was adminïstered at baseline. Participants’ most recent
viral load and CD4 counts were obtained from their medical chart with participant consent.
CDC disease stage (1993 classification system (Castro et al., 1992); asymptomatic,
symptomatic, AIDS) was derived based on the medical information provided (HIV-related
medical conditions and CD4 Lymphocyte counts).
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Alcohol use problems were measured with the Alcohol Use Disorders
Identification Test (Saunders et al., 1993). The AUDIT is one of the most widely used
scales to screen for hazardous or harmful alcohol consumption. This 10-item self-reported
questionnaire probed about domains of alcohol consumption, drinking behaviour, and
alcohol related problems within the Iast year. The items are weighted on a 4-point scale and
the total score ranges from O to 40, with a cut-off point of 8 and higher representing a
strong likelihood of hazardous or harmful alcohol consumption. Earlïer studies (Maltby,
Lewis, & Hill, 2000) have found good internai consistency, with coefficient alphas ranging
from .75 to .94. The sensitivity of the scale to predict alcohol abuse and / or dependence
based on the DSM-IV criteria has been found to range from 38% to 100%; lower prediction
levels usually appiying to very heterogeneous primary care samples.
Drug use problems were measured with the Drug Abuse Screening Test-20
(Skinner, 1982). The DAST-20, a 20-item self-reported questionnaire, has for purpose to
identify individuals who are abusing psychoactive drngs and quantify the degree of
problems related to drug use. It focuses on aspects of drug dependence such as difficulty to
stop using drngs, withdrawal symptoms and consequences of drug use on different life
domains. Participants are asked to indicate if thcy agree or disagree with each statement by
checking the “yes” or “no” answer. The summary score, ranging from O to 20, is
calculated by summing ail items endorsed that are in the direction of increased drug
problems. A score of 6 or above is indicative of problems related to drug use. More
specifically, scores from 1 to 5 indicate low level of problems, scores from 6 to 10 ïndicate
moderate level of problems, scores greater than 11 indicate substantial to severe level of
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problems due to drug abuse. In previous studies with groups of drug abusers (Conoley,
Impara, Mwphy, & Buros, 1996), internaI consistency ranged from .74 to .86. The DAST
20 is derived from an original 28-item version (DAST) and most of the other validation
data available was produced by this earlier version. However, the two versions were found
to be almost perfectly correlated (r=.99). In earlier studies (Gavin, Ross, & Skinner, 1989),
the DAST had been found to have good convergent and discriminant validity.
furthermore, correlations of .74 and .75 were found between DAST scores and DSM-I1
diagnosis of lifetime and current dmg abuse / dependence.
Symptoms of depression were measured with the Beck Depression Jnventory-II
(Beck, Steer, & Brown). This 21-item self-reported scale measures the presence and the
severity of depression in aduits. II was developed based on diagnosis criteria of depressive
disorders of the American Psychiatric Association’s Diagnostic and Statistical Manual of
Mental Disorders Fourth Edition (DSM-W; 1994). Individuals are asked to indicate which
statement best describes the way they have been feeling over the past two weeks. Each item
is rated on a 4-point scale with total scores ranging from O to 63. Scores from O to 13
indicate minimal depression, 14 to 19 mild depression, 20 to 28 moderate depression, and
29 to 63 severe depression. This scale has been found to have good psychometric properties
(Beck et al., 1996), with a coefficient alpha for an outpatient population of 0.92, and a test
rctest reliability of 0.93 over a one-week interval. It was also found to have good
convergent and discriminant validity. The structure of the BDI-II is based on two main
factors: a Somatic-Affective dimension and a Cognitive dimension. Somatic items in the
BDI have been reported to confound the assessment of depression in symptomatic HIV
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infected individual or individuals living with AIDS because these items may represent
symptoms of HIV. In a previous study (Savard, Laberge, Gauthier, & Bergeron, 1999),
symptomatic patients and AIDS patients had higher score than asymptomatic patients on
somatic items of the subscale, but flot on cognitive or affective items. Because of these
resuits, both the total score and the cognitive sub-score (regrouping pessimism, past failure,
guilty feelings, punishment feelings, seif-dislike, sclf-criticalness, suicidai thoughts or
wishes, and worthlessness) were tested in the analyses. Scores on the cognitive dimension
range from O to 24.
Medicai symptoms due to illness or side effects of medication were assessed with a
Symptom Questionnaire, which covers a list of 21 symptoms of HTV or side effects of
medication commonly experienced by HIV-infected individuals. This symptom
questionnaire was devcloped and modified by clinical experience and questionnaires used
in different studies (Ammassari et al., 2001; Vogi et al., 1999; Whalen, Antani, Carey, &
Landefeld, 1994). This questionnaire has adequate face validity and represents common
symptoms reported by HW-infected individuals. In this symptom questionnaire,
participants are asked to put a check mark to indicate if they experienced each of the 21
symptoms in the past two weeks.
Behefs about HIV medication efficacy were measured with two questionnaires:
The HIV Medication Expectation questionnaire-1 (HEXP-1) consisted of items
covering beliefs about medication that were similar to those included in a recent study
(Paterson et al., 2000). Participants were asked to rate on a 3-point Likert scale (0= not at
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ail confident I = somewhat confident an 2= very coifldent) how confident they were
that their anti-HW agents would: (1) prolong life, (2) prevent symptoms, (3) boost
immunity, (4) complement other agents, (5) improve functioning and (6) increase well
being. A total score on this scale was calculated with scores ranging from O to 12. Higher
scores indicated more positive beliefs about the medication efficacy. The Cronbach’s alpha
with the current patient sample was .89, which indicates good internai consistency.
The HIV Medication Expectation questionnaire-2 (HEXP-2) was adapted from the
Medication Attribution Scale (MAS) (Aversa, Kimberlin, & Segal, 199$) to inciude both
the negative and positive impact of HAART (the MAS focuses only on the negative
aspects). The positive impact of medication was assessed with the following question:
‘$pecifica11y regarding HAART medications, how much benefit are you receiving or
expect to receive from these medications”. Participants were asked to rate on a 4-point
Likert scale (O=none, 1=a littie, 2=some, 3=a lot) how much this applied to the following
areas of ftmctioning: (1) energy level and/or appetite; (2) general well-being; (3) restored
libido/sex drive; (4) capacity to perform daily activities; (5) likeiihood of returning to part
time or fuil-time work. The total score on the positive impact of medication ranged from O
to 15, with a higher score representing more perceived positive impact of medication.
Negative impact of medication was assessed by asking participants how much (O=iio effect,
1=rniÏdly, 2=moderately, 3=strongly) the medication has negatively affected them in
different areas offunctioning. Spheres offunctioning assessed were: (1) time spent on work
or other activities; (2) ability to accomplish daily activities; (3) work or activities you
wouid iike to do; (4) ability to work at ajob or go to school; (5) ability to work around your
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home; (6) ability to care for yourse1f (7) social activities. The total score at this negative
impact scale ranged from O to 21, with a higher score representing more perceived negative
impact of medication. When measured with the current sample, both of these subscales had
adequate internai consistency with Cronbach’s alphas of .76 for the positive impact scale,
and .90 for the negative impact scale.
Adherence to medication was measured with an Individualized Medical Monitor
(IMM), which bas been adapted from the AACTG Adherence follow up Questionnaire
(Chesney, Ickovics et al., 2000). The IMM is an individualized questionnaire that first gives
a brief description of the participant’s prescribed medication and asks him if it represents
accurately his current regimen (e.g.: “The following should be an accurate description of
the medicines currently prescribed by your doctor: 150 mg 3TC:1 white diamond piil twice
per day; 40 mg d4T: 1 brown piil twice per day; 400 mg Crixivan: 2 white and green puis
twice per day; 100 mg Ritonavir: 2 beige puis twice per day”). 1f it represents accurately
the participant’s regimen, he is askcd to circle how many times (none, once, twice, IXÇ 4Ç
?) he took each type of medication in the past 7 days, starting from yesterday. A missed
dose was deftned as omitting an entire scheduled dose of one medication. The number of
missed doses for each day is calcuiated by subtracting the number of doses actually taken
from the number of doses each participant was expected to take. These missed doses are
then added for the 7 day-period covered by the questionnaire and divided by the number of
doses the participant was expected to take during that same period of time. This resuit is
finally multiplied by 100 to provide a percentage of suboptimal adherence to the prescribed
regimen.
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Overvicw of analyses
Descriptive analyses were used to study the distribution of the variables and to
evaluate the prevalence ofmissing responses.
Before running the analyses, alcohol use problems were stratified into: no alcohol
problem vs. alcohol problem. Because of low prevalence of severe dmg use problems,
resuits of the DAST-20 were stratified into the following categories: no drug problem, low
level of drug problem, moderate to severe level of drug problem (scores from 6 to 20).
Before using the adherence data in the analyses, effect of inclusion into a treatment
program to improve adherence for a subgroup of subject was tested with a non parametric t-
test comparing average adherence in the month preceding the intervention and average
adherence in the following month.
Univariate analyses were performed with chi-squares and t-tests to study the
relationship between adherencc status (adherence vs. suboptimal adherence) and each ofthe
potential risk factor. A logistic regression was performed afierward to identify potential risk
factors of suboptimal adherence among the following participants’ variables: (1)
demographic characteristics: age, and education; (2) HIV-related medical characteristics:
CDC-93 disease stage (asymptomatic, symptomatic, AID$), and number of medical
symptoms due to illness or side effects of medication; (3) psychosocial characteristics:
alcohol problem/no alcohol problem, no dmg problem/low level of drug problem/moderate
to severe level of drug problem. total score at the depression scale, cognitive score at the
depression scale; and (4) patients’ beliefs about medication efficacy measurcd by two
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different scales: (a) positive bcliefs about medication efficacy (HEXP-1), (b) positive
impact of medication, and negative impact of medication (HEXP-2). for most of the risk
factors, both the average and the “worst” score per interval were retained in the analyses.
The only exceptions were alcohol use problem, and drug use problem which were stratified
based on the “worst” score at the questionnaires. Ail potential risk factors were entered into
two logistic regression models that used different outcome measures: the average self
reported adherence, and the “worst” self-reported adherence. However, because these two
models generated similar resuits, only the logistic regression model using the ‘worst” self
reported adherence measure as the outcome variable wili be reported here. furthermore, the
“worst” adherence measure represents the closest measure to clinical reality since self-
reports generalÏy tend to overestimate adherence rates when compared to more objective
measures such as electronic devices (Liu et al., 2001).
A forward stepwise logistic regression was used to insure validity of the resuits.
Therefore, variable entry was based on the likelihood ratio test and the probability to enter
value was set at 0.05 with a removal value of 0.10. Afier this sequential selection was
completed, the logistic regression model was re-adjusted on the significant variables only in
order to have the maximum number of subjects with no missing observation. Categories of
reference were fixed to represent an “ideal” adherent patient with the following
characteristics: no alcohol problem, no drug problem, no depressive symptoms, no medical
symptoms, and strong beliefs about medication efficacy.
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finally, we explored the relationship between beliefs about medication efficacy
and the foliowing characteristics: (1) demographic characteristics such as age, gender, and
education; (2) HIV-related medical characteristics such as CDC-93 disease stage
(asymptomatic, symptomatic, AIDS), number of medical symptoms due to illness or side
effects of medication, viral load, and hospitalization in the past 6 months; (3) depressive
symptoms. These relationships were explored with Pearson’s correlations, t-tests, and one
way ANOVA with a Tukey HSD contrast test. Note that the N varies from 6$ to $2 in the
analyses because ofthe presence ofmissing values.
Resuits
Descriptive resuits
Eighteen participants (23% of 7$) had an alcohol use problem, while 46 (58% of 79)
had low level of drug use problems, and 16 (20% of 79) had moderate to severe level of
drug use problems. Descriptive information for other predictors is shown in Table W (p.
69).
Impact of adlierence intervention
Among 82 smdy participants, 10 were included in an intervention program (MAX
HAART) during the one-year duration of the larger study because they had reported
adherence difficulties. No significant impact of treatment was noted when comparing
adhcrence resuits before and afier the intervention program for each of these individuals
(p .06).
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Resuks of univariate analyses
0f ail the different variables tested with univariate analyses, the only variables
significantly associated to suboptimal adherence were: alcohol use problems (x2(i. N 6$)
= 7.372, p= .009), drug use problems (x2(2 N= 69) 6.959, p= .03 1), the worst score with
respect to beliefs about medication measured with the HEXP1 questionnaire (t (70) = -
2.42, p= .02) and the average score with respect to beliefs about medication measured with
the HEXPY questionaire (t (70) = -2.35, p= .02). However, suboptimal adherence was flot
significantly associated with beliefs about medication measured with the HEXP2 positive
impact scale (t (70) = -.27, p= .79), and the HEXP2 negative impact scale (t (70) = 1.66, p
.10). 0f the 70 individuals included in the univariate analyses, 29 had suboptimal adherence
to HAART.
Resuits of logistic regression
Because of missing data, 6$ HIV-infected individuals were available to be included
in the logistic regression. Among this group of individuals, 27 (39.7%) had suboptimal
adherence to HAART. Ail potential risk factors were tested in a logistic regression model
predicting suboptimal adherence to HAART. The same variables that were associated with
suboptimal adherence in the univariate analyses were also risk factors for suboptimal
adherence in the logistic regression model. Variables retained in the final regression model
(x2 21.33, df= 4, p = 0.000) were: alcohol use problems (x2 7.3, df 1, p0.007), drug
use problems (x2= 6.4, df= 2, p=0.O4), and beliefs about medication efficacy measured with
the HEXPY questionnaire (x2= 7.6, df= 1, p=O.006). Only the “worst” score of beliefs about
45
medication efficacy was retained in this model, but the “worst” score and the average
score of beliefs about medication efficacy at the HEXP1 were highly correlated (r= .999,
N= 82, p.OOO). With these risk factors, the efficiency (overali proportion of individuals
adequately classified across classes (adherence vs. suboptimal adherence)) in our sample
was 78%.
Results ofthe Iogistic regression (sec Table V and Table VI, pp. 70-7 1) indicate that
participants who have an alcohol use problem are 5 times more likely to have suboptimal
adherence to HAART than participants without an alcohol problem. Also, for every one
point increase in the degree of confidence about medication efficacy at HEXP1 scale, the
risk of having suboptimal adherence to HAART decreases by 0.7 times. finally, having a
drug use problem is globally significant in the model, which means that it increases the risk
of suboptimal adherence. However, it is not possible to know how much it increases the
risk of suboptimal adherence because no differential effects were detected between the two
levels of dntg problems (low level of problem, and moderate to severe level of problem)
with the Wald statistical test.
Because we expected that number of medical symptoms due to illness or side effects
of medication, as well as the cognitive score at the depression inventory, would be
associated with suboptimal adherence, we subsequently forced each of them in a logistic
regression model to test their level of significance. The model was flot significantly
improved when forcing in the number of medical symptoms ( 0.848, df 1, pO.357),
and cognitive symptoms of depression (x2 0.909, df 1, pO.340).
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Factors associated with beliefs about medication efficacy
Beliefs about medication efficacy measured with the HEXPY were positively
correlated with the positive impact scale of the HEXP2 (r = .511, N= 82, p=.000), and
negatively correlated with the negative impact scale of the HEXP2 (r = -.294, N= $2,
p=.007).
Beliefs about medication efficacy were flot associated with demographic variables
such as age (r = .028, N= 82, p=.$O), gender (t ($0) = .17, p.$7), and education level (r =
.007, N= 82, p=.95). However, beliefs about medication efficacy measured with the
HEXP 1 were negatively correlated with the number of medical symptoms due to illness or
side effects of medication reported in the past two weeks (r -.26, N= 79, p= .02), and also
negativcly correlated the total score at the depression inventoly scaïc (r = - .27, N 71,
p.O2). However, there was flO correlation between HEXP1 score and the cognitive
subscale at the depression inventory (r = -.13, N= 71, p=.27). Beliefs about medication
efficacy were flot significantly correlated with the following medical indicators of health
status: viral load (r = -.17, N= $0, p= .13), and having been hospitalized in past 6 months
(t=1 .25(80), p .22). However, a one-way ANOVA revealed a globally significant
difference in means on beliefs about medication efficacy at the HEXPY questionnaire as a
function of disease stage (f(2, 77) = 3.31, p .04). Whcn using a Tukey contrast test, it
showed that individuals wïth AIDS (M 9.13, SD = 2.97) had significantly higher scores
on the beliefs about medication questionnaire than individuals who were symptomatic (M =
7.35, SD 2.82; HSD = 1.77, p = .04). No significant difference in beliefs about
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medication efficacy was detected between individuals who were at the asymptomatic
stage (M = 8.93, SD = 2.31) and the two other disease stages.
Discussion
Resuits of this study are generally consistent with previous research published on
risk factors for suboptimal adherence to HAART. It replicated known resuits about the
negative impact of alcohol and drug use problems, and confirmed the impact of beliefs
about medication efficacy on adherence to medication.
Rates of suboptimal adherence reported in this study were comparable to rates
reported in other studies (Carrieri et al., 2001; Nieuwkerk et al., 2001) but only a few
studies have measured adherence over time. The logistic regression model highlighted
important risk factors for suboptimal adherence. ilaving less positive beliefs about
medication efficacy, as measured with the HEXPÏ questionnaire, was identified as a risk
factor for suboptimal adherence to I-LkART. Therefore, people who have more negative
expectations about HIV medication effect on their health might need to be more cïosely
monitored. Alcohol and drug use problems were also identified as risk factors for
suboptimal adherence to HAART. In addition to measuring hazardous or harmful alcohol
consumption and drug problem, the questionnaires used for this study assessed the impact
of alcohol use and drug use on different I ife domains within the past year. More
specifically, these questionnaires asked about serious consequences of alcohol or drug use
on daily living and interpersonal relationships, which rdflects the social instability that is an
integral part of a substance abuse diagnosis based on the DSM-IV criteria. Restiits of our
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study indicated that alcohol consumption and dmg use that negativeÏy affected different
life domains within thc past year, did increase the risk of suboptimal adherence. However,
our study, alcohol use problem was more clearly related to suboptima! adherence to
HAARY than drug use problem. Drug problem was globally significant in the mode!, but
its impact on suboptimal adherence was not as clear because it entered in the model at the
limit of significance. Furthermore, probably because of the small sample size we were flot
able to distinguish between differential effects of drug use problems on suboptimal
adherence. This cou}d also be explained by the fact that we grouped moderate to severe
problems in the same category, therefore combining different levels of risk. However, it
was flot possible to test moderate, substantial, and severe levels of drug problem separately
because oftheir low prevalence. Furthermore, this resuit might aÏso be expÏained by the fact
that we did flot distinguish between types of recreational drugs used by participants, since
different drugs might have different impact on adherence.
Alcohol use problems and beliefs about HW medication efficacy werc clear risk
factors for suboptimal adherence to HÀART that would need to be monitored carefully in
clinical practice. Drug use problem would also need to be taken into consideration as a
potential risk factor for suboptimal adherence, but more studies would be needcd because
its association with suboptimal adherence was not as significant. Because of the large
confidence intervals in the odds ratio for the three risk factors of suboptimal adherence
reported here, it is flot possible to know accurately how much each of these factors
increased the risk of suboptimal adherence to HAART. Therefore, because of the current
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sample size, it was flot possible to have an exact estimation of elevation in risk of
suboptimal adherence and this would need to 5e studied further.
As expected, demographic variables, and disease stage were not associated with
suboptimal adherence. However, contrary to our initial hypotheses, a bigher number of
medïcal symptoms due to illness or side effects of medication was flot significantly
associated with suboptimal adherence. This might partly be explained by the fact that the
population studied here reported a relatively low number of medical symptoms.
Furthermore, we did flot take into consideration the types of medical symptoms reported by
participants. We would in fact expect that gastrointestinal symptoms such nausealvomiting,
which are usually more bothersome and are among the principal causes of medication
discontinuation (OBricn et al., 2003), would have a stronger impact on adherence. Also,
the symptoms covered by the questionnaire might not have been representative of the most
bothersome symptoms (for example, diarrhoea was flot included in the list). Also in
contradiction with mir initial hypotheses, a higher number of depressive symptoms was flot
significantly associated with suboptimal adherence. This lack of association might have
been causcd by the low prevalence of depression in the sampic, and also partly by the type
of measure used. Because our measure of depression included medical symptoms, we also
tested the cognitive sub-score that might flot have been sensitive enough to detect
depressive affect in our medical sample.
It is interesting to note that only beliefs about medication efficacy measured with
the HEXPÏ questionnaire were associated with suboptimal adherence, white we did flot
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detect any significant association between resuits at the two subscales of the HEXP2
questionnaire (positive impact of medication / negative impact of medication) and
suboptimal adherence, both in the univariate analyses and in the regression model. This
seemed to indicate that these questionnaires measured two different theoretical concepts:
the HEXP1 was centered on global beliefs about medication effect on health, while the
HEXP2 referred to quality of life issues and expectations about the positive or the negative
impact of medication use on daily functioning. The strong association between the HEXPI
and the positive impact scale of the HEXP2 was expected because of the strong link
between global beliefs about medication effect on health and perceived benefits of
medication on level of functioning. In fact, global functioning might be one aspect that
influences the type of beliefs a person holds about bis or her medication. However, it was
surprising to find a smaller association between the HEXPÏ and the negative impact scale
of the HEXP2. This might indicate that people’s global beliefs about medication efficacy
are more strongly affected by the positive impact rather than the negative impact of
medication on daily functioning.
An exploration of factors associated with beliefs about medication efficacy
measured by the HEXP 1 questionnaire showed that a higher number of medical symptoms
and a higher total score at the depression inventory were associated with less positive
beliefs about medication efflcacy. However, because the cognitive symptoms of depression
were not associated with beliefs about medication efficacy, it might be that the relationship
between the depression inventory total score and beliefs about medication efficacy
(HEXP1) was artificially creatcd by the scale’s somatic items reflecting medical symptoms
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ofHIV or side effects ofmedication. These somatic items are: loss ofenergy, changes in
appetite, changes in sleeping pattem, tiredness or fatigue. This finding that beliefs about
medication seemed to be less positive as the number ofmedical symptoms increased, raises
an interesting question: could beliefs about medication efficacy be partly based on the
number of medical symptoms people are experiencing?
It was surprising that beliefs about medication cfficacy were flot associated with
viral load or hospitalization in the past 6 months, both of which constitute important
markers of HIV disease progression. This might indicate that people’s beliefs about the
effect of medication on their health are less related to the clinical reality, and more a
function of their own perception. However, the lack of association could also be explained
by the fact that our measure of viral load was flot necessarily taken at the same time as
people filled the beliefs questionnaire since it was taken from their most recent medical
exam. Therefore, their clinical status might have been somewhat different when they filled
the belief questionnaire. We detected an association between beliefs about medication and
disease stage: people with an ADS diagnosis held more positive beliefs about their
medication than people at the mildly symptomatic stage. This result seems to be partly in
line with other published studies stating that more severely iii patients perceived a stronger
relationship between suboptimal adherence to medication and AIDS-related complications
(Gao et al., 2000; Molassiotis et al., 2002). However, this association seems to be
contradicted by the fact that disease stage was not associated with adherence to HAART in
our smdy. Since number of medical symptoms seemed to influence beliefs about
medication. this distinction between AIDS and symptomatic stage is interesting because
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this might mean that people interpret differently the symptoms that they have as they are
diagnosed with AID$. For those individuals with an AIDS diagnosis. symptoms might be
perceived accurately as a progression of the disease, because they are more serious and can
directly be associated with AIDS. In contrast. those at the mildly symptomatic stage, might
misread less serious symptoms as side effects of medication. However, because the
association was at the limit of significance, it would nced to be tested again before making
any finner conclusions.
This study has several limitations that reduce the generalizability of the findings.
first, because of a seÏf-selection bias, participants included in our sample were flot ftilly
representative of the general population of HIV-infected individuals (i.e., this sample was
primarily a sample of Causasian gay men). Participants excluded from the study sample
were different from the final sample on two aspects: they tcnded to have a lower income
and to report intravenous drug use as a risk factor for HIV more often than individuals in
the study sample. It is also possible that adherence rate might have been biased by the use
of a self-reported scale, which usually tends to overestimate adherence. It was originally
planned to also measure adherence with Medication Event Monitoring Systems (MEMS)
for a sub-group of participants to validate self-reports, but participants rcfused to use them
because of convenience issues. However, self-reported adherence questionnaires have been
found to be adequate adherence measures because of their correlation with other measures
of adherence (Deeks. 2000; Duong et al., 2001; Hugen et al., 2002), and their abillty to
predict therapeutic outcome. as measured by HIV RNA level and CD4+ ceil count
(Mannheirner et al., 2002; Walsh, Mandalia et al., 2002). Because of the design of this
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study, we could flot control for several variables such as: changes in medication regimen
over the 6-month period, time since tested HW-positive, and type of HAART medication
taken. Finally, the current sample size might have affected our ability to detect smaller
associations.
Despite these limitations, this study has several clinical implications. f irst, it
confirms the detrimental impact of alcohol use problems on adherence to medication. This
highlights again the importance of screening for these problems in clinical practice to
provide adequate help to patients with difficulty adhering to their medication regimens. It
aÏso reinforces the importance of beliefs about medication efficacy in HIV-infected
individuals’ decision to adhere to treatment or not. Therefore, it is essential to get a better
understanding of how HIV-infected individuals perceive their medication to be able to
intervene more effectively in clinical practice. Learning about factors associated with
beliefs about medication will eventually guide us in our understanding of how these beliefs
develop. It might provide the key to understand how to help HIV-infectcd individuals in
modifying beliefs that might flot be based on factuai information.
In future studies, it would be interesting to explore more thoroughly beliefs about
medication in association with other psychological variables. finally, because adherence
might be difficult to predict while using only participants’ characteristics, it is essential to
study more complex models based on sound theories. The impact of beliefs about
medication on adherence, and the association between beliefs about medication and somatic
symptoms need to be studied further. It would be interesting to test whether these
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associations can be understood within a “self-regulatory mode!” (Leventhal, Diefenbach,
& Leventhal, 1992). TItis model views adherence as a self-reguÏatory processs (equivalent
of a coping mechanism) in which individuals adapt their medication taking behaviour as a
function of the context in which they are. In this mode!, it is believed that people make
adherence decision based on several factors, especially their own interpretation or beliefs
about somatic symptoms.
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Table 111. Demographic Characteristics of Participants (N=$2)
Characteristic N % Mean (SD)
Age (years) 41.0 (7.2)
Education (years) 13.3 (2.3)
Monthly income ($) 1382.90 (972.3 1)
Time since tested HIV-positive (months) 99.4 (50.6)
Gender
Male 71 86.6
Female I 1 13.4
Race
Caucasian 66 80.5
Black 8 9.8
Other 6 7.3
Relationship status
Single 56 68.3
Living with partner 26 3 1.7
Work status
Working 66 80.5
Not working 16 19.5
On long-term disability*
Yes 65 79.3
No 5 6.1
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Characteristic N % Mean (SD)
Number of risk factors for HW
Only one 66 80.5
Morethanone 14 17.1
Type ofrisk factor(s) for HW
Same sex sexual contact 62 75.6
Heterosexual sexuat contact 16 19.5
Intravenous drug use 11 13.4
Blood Transfusion 2 2.4
1993 CDC Classification (N=80)
Asymptomatic 15 18.3
Symptomatic 26 3 1.7
AIDS 39 47.6
Type ofmedication regimen
NRTI + PI 40 48.8
NRTI + NNRTI 24 29.3
NRTI+NNRTI+PI 15 18.3
3NRTIs 1 1.2
Viral load
Undetectable 39 47.6
Detectable: <35 000 33 40.2
Detectable: > 35 000 8 9.8
*Missing data n12
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Table IV. Descriptive information of predictors
Variables Mean (SU)
Depression scores (N=7 1)
Highest total score at BDI 15.76 (12.62)
Average total score at BDI 11 .50 (9.50)
Highest cognitive score at BD! 4.93 (5.56)
Average cognitive score at BDI 3.14 (3.89)
Beliefs about medication (N=82)
HEXP1:
Lowest total score 8.50 (2.93)
Average total score 8.52 (2.93)
HEXP2:
Positive scaÏe:
Lowest total score 8.11 (3.57)
Average total score 8.12 (3.5 7)
Negative scale:
Highest total score 7.2$ (5.91)
Average total score 7.27 (5.89)
Medical symptoms (SYM2) in the past 2 weeks (N79)
Highest number ofsymptoms 4.20 (4.37)
Average number of symptoms 4.1$ (4.35)
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Table V. Summary of Logistic Regression Analysis Predicting Suboptimal HAART
Adherence (N6$)
Variable B SE Odds Wald 95% Confidence
ratio statistic interval
Lower Upper
Alcoholproblem 1.615 0.737 5.02$ 4.801* 1.186 21.315
Drug problem:
Minimal problem -0.15 1 0.759 0.860 0.040 0.194 3.80$
Moderate to severe problem 1.756 0.974 5.791 3.248 0.858 39.107
Positive bel iefs about medication -0.347 0.124 0.707 7.782** 0.554 0.902
*12<.05. **p<Ol
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Table VI. Classification Table for Predictors of Suboptimal HAART Adherence (N6$)
Observed Adherence Level Predicted Adherence Level
AdherentNon adherent Correct percentage
Non adherent 17 10 63.0
Adherent 5 36 87.8
Overali Percentage
Model Coefficient: 21.32$, df 4, p = 0.000
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Abstract
This exploratory study examines barriers to adherence more specifically defined as the
reasons reportcd by participants for suboptimal adherence to J-IAART at their “worst”
adherence episode within a one-year period. It also explores facilitators of adherence
defined in this study as strategies and motivators that help facilitate adherence to HAART
reported by HIV-infected individuals. Types of facilitators reported are explored in relation
to participants’ demographic characteristics. Number and types of facilitators reported are
tested in relation to adherence status measured over one year. Eighty-two participants were
recruited for this study. Reasons most often reported for missing medication are
interferences with daily routine. Main categories offacilitators reported are: 1) planning
sidils; 2) positive perception of medication; 3) social support; 4) commitment I intemal
motivation; 5) seif-care. Some ofthese facilitators are associated with participants’
characteristics, but flot with adherence status. Clinical implications ofthese resuits are
discussed.
Key Words: Medication adherence — antiretroviral therapy — HW-infection — barriers —
facilitators
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Introduction
The advent of Highly Active Antiretroviral Therapy (HAART usually defined as a
Protease Inhibitor (PI) or a Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)
combined with at least two other antiretroviral drugs) has greatly improved the life
expectancy, as well as the quality of life of HIV-infected individuats. HAART regimens
have becn associated with delayed HIV progression, decreascd risk of getting opportunistic
infections, decreased hospitalization frequency and lower death rates due to HIV (Altice &
Friediand, 199$; Carpenter et al., 2000; Chun & fauci, 1999; Dceks et al., 1997; Karon et
al., 2001; Paul et al., 1999). However, HAÀRT regimens are usually oniy effective against
the HIV virus when taken as prescribed, and might therefore necessitate life long adherence
to control viral replication.
Adherence to treatment is known to be problematic regardless of the type of disease
or treatment, especially when medications need to be taken over a long-term basis
(Blackwell, 1973; Myers & Midence, 199$). Adherence to HIV medication is further
complicated by the fact that HAART regimens are ofien very complex and can have
numerous negative side effects. Individuals on HAART rcgularly need to take a large
quantity of medication on a tight and regimented schedule, with special requirements
associated with each type of medication taken (e.g., dietaiy restrictions); while having to
tolerate various side effects. These drug regimens also require a higher threshoÏd of
adherence in order to be effective and to avoid the development of resistance to medication.
The current recognized threshold of adherence for optimal virologic outcome is 95% of
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doses taken as prescribed, especially when protease inhibitors are part of the medication
regimen (Paterson et al., 2000). Consistency of adherence over time is also critical because
patients who are generally highly adherent but who missed their medication on a few
occasions have been found to develop resistance to medication (Bangsberg et al., 2000;
Pemo et al., 2002; Walsh, Pozniak et al., 2002). Suboptimal level of medication exposures
may permit viral replication in the presence of drug leading to the emergence of drug
resistant viruses (Clavel & Hance, 2004; Condra et al., 2002). Patients with suboptimal
adherence may then be confronted with reduced treatment options, increased risk of
therapeutic failure and/or increased risk of transmitting a resistant strain of the virus to
someone else.
Reported rates of adherence in HIV-infected individuals vary widely in the literature
but are often suboptimal (Gifford et al., 2000; Kleeberger et aÏ., 2001; Nieuwkerk et aï.,
2001), especially when measured over time (Mannheimer et al., 2002; Roca, Gomez, &
Arnedo, 2000). Taking into consideration that adherence to HAART has serious
implications for the treatment of HW-infected individuals, as well as for public health,
there is a critical need for a better understanding of factors that may be associatcd to
adhcrence behaviours.
In the last decade, several factors associated with adherence to medication were
studied. These factors, which have more or less consistently been linked to adherence, have
been grouped into four different categories (Boucher & Veilleux, 2002; Chesney, 2000,
2003; Lafeuillade, 2001): (1) patient-related factors, such as demographic and personality
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characteristics, depression, and beliefs about treatment; (2) medication-related factors,
such as complexity of treatment and frequency of dosing; (3) doctor-patient relationship
and other social support; (4) general system of care. However, despite a considerable
amount of research, it is still impossible to predict accurateÏy which individuals are at most
risk of suboptimal adherence and may necessitate intervention programs. The main
objectives of this study are: (1) to describe and compare in a group of HIV-infected
participants both the barriers of adherence, defined more specifically as the self-reported
reasons for missed medication doses, and the facilitators of adherence, defined as the self
reported strategies and motivators that help facilitate adherence to HAART; (2) to explore
the potential association between the types of catcgory of facilitators reported and
participants’ demographic characteristics (age and education); (3) to explore the potential
association between the number or types of identified categories of fadilitators uscd by
participants and their adherence status over a one-year period.
In terms of previous findings, several recent quantitative and qualitative studies
have explored the types of reasons for missed medication doses reported by patients to gain
a better understanding of adherence behaviours. There is consistency in the type of reasons
most frequently mcntioned in several recent quantitative studies that have used similar self
reported questionnaires to assess reasons for suboptimal adherence (Catz et aL, 2001;
Chesney, 2000; Chesney, Morin et al., 2000; DeMasi et al., 2001; Eldred et al., 199$;
Ferguson et al., 2002; Gifford et al., 2000; Kleeberger et al., 2001; Mannheimer et al.,
2002; Molassiotis et al.. 2002; Reynolds et al., 2004). In all these studies, the most
commonly cited reason for missing medication was forgetfulness. Other common reasons
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mentioncd incÏude: changes in daily routine, interference of social context (such as being
too busy, being away from home, eating a mea! at a wrong time. sleeping through a dose),
and practical barriers such as comp!exity of drug regimen and number of medications to
take. A greater number and/or intensity of reasons for missed medication doses has
generally been associated with lower adherence levels (ferguson et aL, 2002; Walsh,
Home, Dalton, Burgess, & Gazzard, 2001).
0f the qualitative studies that have focused on the reasons for missed doses, there
are generally similar reasons cited (Laws, Wilson, Bowser, & Kerr, 2000; Proctor, Tesfa, &
Tompkins, 1999; Ryan & Wagner, 2003): forgetting or deciding flot to take the medication
because of interferences with daily routine, complexity of the regimen to follow, presence
of medication side effects, and factors associated with the social/physical cnvironment such
as being in a public or unfamiliar environment which makes it more difficuit to follow
dietary requirements or to avoid that others sec them taking their puis.
Most of the adherence smdies, have focused primarily on obstacles or barriers to
adherence, while, to our knowledge, only Pvo published stadies have explored facilitators
of adherencc. Roberts (2000) used in-depth interview to coilect data from 2$ HIV-infected
patients, including both men and women who had been taking a P1-based antiretroviral
cocktail regimen for at Ïeast three months prior to the interview. Participants in this study
reported six main facilitators of adherence: (1) use of mechanical devices such as alarm
dock and!or pilibox; (2) “making a commitment” to take the medication and having the
necessary self-discipline to take it; (3) “routinizing”, which consisted of integrating
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medication taking into their daily routine; (4) confidence about medication effects on
their health and the belief in its necessity; (5) social support, such as friends and familv
members reminding patients to take their puis or giving them more concrete support; and
(6) general support from health care provider, especially information and advices provided
by their doctor.
A second qualitative study (Remien et al., 2003) used in-depth interviews to collect
information about facilitators of adherence in a sample of 152 HIV-infected men, women
and injection drug users and found similar resuits. One of the strongest facilitators reported
was the belief that the treatment was beneficial and necessary for health and survival, and
that not taking it might lead to illness. Respondents mentioned using several sources of
information, such as blood test rcsults, subjective experience of energy levels and physical
symptoms, to make their personal judgment about the efficacy of the medication. Among
other facilitators were: (1) faith in health care professionals; (2) motivation to take care of
themselves as a reason for taking the medication; (3) use of alternative or complementary
therapies to treat HIV, improve overali health and well-being, or to reduce side effects of
medication; (4) use of practical dcvices to remember to take the medication (e.g.: beepers,
medication organizers, etc.), and for contingency planning; (5) staying healthy being a
priority; (6) social support; and (7) desire to live long enough to take part in future. To our
knowledge, the relationship between these different categories of facilitators and adherence
rate has flot been studied.
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It would appear that a more thorough exploration of fadilitators of adherence
might bring a new perspective to this field by identifying and building on motivators and
strategies already adopted by HIV-infected individuals in their day-to-day life to facilitate
adherence behaviours. furthermore, comparing these strategies and motivators of
adherence behaviours (facilïtators) with the reasons most frequently reported for
suboptimal adherence (barriers) might also provide more information to guide clinical
interventions.
Methods and materials
Participants
One hundred and nine aduits (N=109) with HIV-infection on HAART treatment
were approached for this study. Twenty-seven participants ofthis sample (24.8%) could flot
be included in the final analyses: 14 (12.8%) dropped out and 13 (11.9%) were excluded
for either their inability to read and write English, inability to complete the questionnaires
in a reliable fashion, or because of alcohol or drug intoxication at the time of the baseline
interview. Comparisons between the excluded participants (N=27) and the final sample
(N=82), using chi-squares and t-tests analyses, showed that groups were comparable on ail
demographic characteristics, HIV disease markers, and indicators of health status, except in
the case of monthly income and type of risk factor for HW. Specifically, participants
excluded from the study generally had a lower income (t (99.9) = 3.42, p = .001) and
tended to report intravenous drug use as a risk factor for HIV more often than individuats in
the study sample (x2(’ N=95) = 5.92, p = .025).
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The final sample was composcd of 82 individuals ofwhom 71 were men (86.6%)
and 11 women (13.4%) with a mean age of 41 years (SD = 7.2; range 21-64) and education
level of 13.3 years (SD = 2.3; range 8-19). See Table VII (p. 110) for a description of
demographic and medical characteristics of participants.
Procedures
Participants were recruited, starting in the Spring of 2000, in the Toronto Metro
Area through comrnunity organizations and Hospital Centers for a larger multidisciplinary
research project on the psychosocial, behavioural and treatment factors associated with
adherence to J-TAART in HIV-infection. The project included two distinct but linked
studies: TNFORIVIM-HAART $tudy (Identification of Necessary factors for Medication
Management of HAART) and MAX-HAART Study (Maximizing HAART Adherence
Through Behavioural Interventions). The LNFORMM-HAART Study used a natural
history design in order to identify the main predictors of HAART adherence over a 12-
month period of time. The MAX-HAART Study compared the tolerability and feasibility
of two distinct adherence-enhancing interventions (solution-focused intervention and
cognitive intervention) with a subgroup of HTV-infected individuals assessed as having
adherence difficulties during their participation in the INFORMM-HAART study. Ah
participants provided written informed consent to participate in this research as approved
by the St. Michael’s Hospital Research Ethics Board. Individuals who gave informed
consent and decided to participate in this research were scheduled for 14 regular 30 to 45
minutes visits over a period of one year to complete a variety of behavioural,
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neuropsychological and psychosocial questionnaires and inventories. Participants
received remuneration for their participation in this study at the rate of $ 1 O-20 per hour
depending on the type and scope of instruments administered.
Measures
The following questionnaires were administered to each participant:
A general demographic questionnaire including questions such as gender, age,
education level, etc. was administered at baseline.
A questionnaire about general and HIV-specific medical status, including questions
on prior opportunistic infections, was administered at baseline. Participants’ most recent
viral load and CD4 counts were obtained from their medical chart with participant consent.
CDC disease stage (1993 classification system (Castro et al., 1992); asymptomatic,
symptomatic, AIDS) was derived based on the medical information provided (HIV-related
medical conditions and CD4 Lymphocyte counts).
Reasons for suboptimal adherence (barriers to adherence) were assesscd by the
Reasons Questionnaire, which included a list of 19 probable reasons why people may have
missed taking their HAART medication. The Reasons Questionnaire contained the 14-item
scale found in the AACTG Adherence Instruments (Chesney, Ickovics et al., 2000), (the
most widely used scale to study reasons for suboptimal adherence with HIV-infected
individuals), and five additional items: (1) slept in late or went to bed carly, (2) lost track of
time, (3) didn’t want to take them. (4) feit too tired, and (5) feit stressed out. This
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questionnaire asked participants to rate on a 4-point Likert scale (O: Neyer, 1: Rarely, 2:
Sometimes, 3. Ojten) how often they missed taldng their medication in the previous week
because of each ofthese 19 reasons.
Strategies and motivators of adhcrence behaviours (facilitators of adherence) were
measured with the Adherence Facilitators questionnaire, which consisted of an open-ended
question created by the research team: “What do you find particularly helpful in your life
that helps you adhere to the HAART medication? That is, things you do for yourself, things
you teil yourself objects that you value, techniques that you find useful, people in your life,
etc. Please describe.”
Adherence to medication was measured with an Individualized Medical Monitor
(IMM), adapted from the AACTG Adherence Follow up Questionnaire(Chesney, Ickovics
et al., 2000). The IMM is an individualized questionnaire that first gives a brief description
of the participant’s prescribed medication and asks him if it represents accurately his
current regimen (e.g.: “The following should be an accurate description of the medicines
currently prescribed by your doctor: 150 mg 3TC:1 white diamond put twice per day; 40
mg d4T: 1 brown pili twice per day; 400 mg Crixivan: 2 white and green pills Pvice per
day; 100 mg Ritonavir: 2 beige puis twice per day”). If it represents accurately the
participant’s regimen, he is asked to circle how many times (none, once, iwice, 3X 4X ?)
he took each type of medication in the past 7 days, starting from yesterday. A missed dose
was defined as omitting an entire scheduied dose of one medication. The number of missed
doses for each day is caicuiated by subtracting the number of doses actualiy taken from the
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number of doses each participant was expected to take. These missed doses are then
added for the 7 day-period covered by the questionnaire and divided by the number of
doses the participant was expected to take during that same period of time. This resuit is
finally multiplied by 100 to provide a percentage of suboptimal adhercnce to the prescribed
regimen.
Design
This is a descriptive, exploratory study using a qualitative methodology to describe
the types of reasons most frequently mentioned by participants at the time of their “worst”
adhcrence level within a one-year period. It also uses a qualitative methodology to establish
categories of adherence facilitators based on the strategies or motivators that HIV-infected
individuals reported using to facilitate their adherence to their HAART regimens. Finally,
ibis study uses a quantitative longitudinal design to evaluate the association between the
number or the type of categories of adherence facilitators mentioned at one time point and
participants’ adherence status measured over a period of one year.
To answer our research questions, it was necessary to render individual reports
comparable through time by organizing the adherence data into 12 fixed intervals of 30
days starting at study entry for a total period of 360 days. However, this resulted in some
participants flot having at least one entry every 30 days. In order to insure that the
adherence measure was reliable, without detrimentalÏy minimizing sample size, we required
that at least 6 measures of adherence out of 12 be available for a subject to be included in
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the analyses. For each 30-day interval, both the average and the “worst” self-reported
adherence percentage were cal culated.
It was flot possible to control time of administration for the Facilitators of
Adherence questionnaire because it was administered only once, at different time intervals
within a period of 360 days of baseline. However, the resuits should be relatively stable
over a period of several months because participants in the study had been taking
medication for a few years and were being asked what generally helped them adhere to
their regimens. It can be reasonably postulated that these individuals had developed a set of
habits andlor strategies to facilitate adherence.
Overview of the analyses
b explore reasons for missing medication, only participants who reported at least
one episode of suboptimal adherence over a period of 360 days were included in the
analyses. We used descriptive statistics to explore the frequency, as well as the intensity of
each reason reported by participants at the week of their lowest adherence within this one
ycar period.
To explore facilitators of adherence, qualitative analyses were conducted based on
multiple readings of participants’ answers to strategies or motivators that usually helped
them adhere to their HAART regimens. The analyses were bascd on Miles and Huberman
mixed approach method to qualitative data analysis (Miles & Huberman, 1994), using
checklist matrices to note patterns and themes emcrging from the data. Categories emerged
$6
from the data without being assumed a priori, but decisions to regroup categories were
later informed by available theories on adherence to medication, as well as prior literature
on the subject. Participants’ answers werc categorized and cventually regrouped into
similar categories. Initial catcgorizations were discussed with a health psychology expert
who has over 30 years of experience in this field of practice. The categories were also
reviewed regularly with the second author, who has 13 years of clinical experience with
HIV-infected individuals. A random sub-sample of participants’ answers representing 15%
of the total number of individuals participating in this study were reviewed and categorized
independently by another rater specializing in health psychology. Ibis independent judge
reviewed the categorizations based on definitions provided for each subcategory (see Table
VIII for definitions, p. 112). Minor changes to the categories’ definitions were made
following inter-rater agreement to improve clarity. The inter-rater agreement rate was
satisfactory, with a Cohen’s Kappa score of .84. Every item for which there was
discordance was discussed until an agreement was reached. Following inter-rater
agreement, categories with overlaps, (i.e. covering similar concepts), were discussed with
the second author and a decision was made to regroup these into larger categories for
clarity, as well as data analysis purpose. In order to count the numbcr of categories
reported, participants’ answers were reduced to presence or absence of a given category. T-
tests analyses were also used to explore the relationship between presence or absence of a
given category of facilitator and participants’ demographic characteristics (age and
education).
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Before using the adherence data information. the effect of inclusion in an
adherence enhancement treatment program for a subgroup of subjects was tested using a
non parametric t-test. This test compared average adherence in the month preceding and
following the intervention.
The “worst” self-reported adherence score was retained as the outcome measure
because it represents the closest measure to clinical reality given that self-reports generally
tend to overestimate adherence (Liu et al., 2001). Participants were classified based on their
adherence status (adherence or suboptimal adherence) using the critical eut-off point of
95% adherence; an accepted criterion in the literature for achieving the best virologie
response. Participants who had missed more than 5% of their medication at least once over
a period of one year were categorized as having a suboptimal adherence status.
Relationships between adherence status and both the number and the type of categories of
facilitators were investigated separately with Chi-square analyses. Note that the N varies
from 63 to $2 in the analyses because of the presence of missing values.
Resuits
Reasons for suboptimal adherence
Forty-two participants (51% of the study sample, N=$2) reported at least one reason
for suboptimal adherence during their worst week ofadherence. Wc used two approaches to
determine the most frequently mentioned reasons for suboptimal adherence (sec Table X, p.
114). Using the highest percentage reported on the scale item “often”, the reasons most
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frequently reported were: “busy with other things” (14%), “didn’t want to take them”
(7%), “was traveling or away from home” (7%), and ‘wasn’t feeling well” (7%). By
collapsing scale items into a dichotomous category: present (“often”, “sometimes” and
“rarcly”) versus absent (“neyer”) the reasons most frcquently mentioned were “busy with
other things” (55%) and “forgot” (55%). Other common reasons were: “slept in late or went
to bed early” (45%), “was traveling or away from home” (43%), “feu asleep/ slcpt through
dose time” (4 1%), “had a change in daily routine” (3 8%), and “wasn’t feeling well” (38%).
Facilitators of adherence
There were 75 participants who completed the open-ended questions about those
factors that facilitated adherence to HAART medication. Seven categories of adherence
facilitators emerged from the data: (1) “planning skills”, (2) “positive perception of
medication”, (3) “social support”, (4) “comrnitmentjinternal motivation”, (5) “seif-care”,
(6) “research participation” and (7) other answers (see Table IX for frequencies, p. 113).
The following is a more thorough description of specific categories of facilitators
mentioned by participants.
1) Planning skiJls:
Most participants (69%) described using several organizationai and general
planning skills to integrate medication into their daily life. This category included two types
of planning strategies: one relying on participants’ “internai resources” to remember to take
medication and another reiying on “external sources” as reminders.
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Among “internai resources”, several participants reported associating their
medication schcdule with their daily activities or daily routine. A typical exampic of these
answers is:
I take my puis at convenient timesJr me: thing in the morning 7:00 AM
I know J can eat afler 8:00 and I usualÏy get zip then. I take my next puis at
3.00 again knowing that between 1:00 and 4:00 is a good time not to eat
because I work etc. the Ïast set at 11:00 is when J go to bed Ifind these
times don ‘t interfere with my hfe and actuallv work with il (JD 201).
Other strategies cited in this category wcre: using localization of puis as a reminder
to take them, as weJl as planning ahead of time, such as having the right type of food
available to take with doses of medication and carrying puis whcn away from home. A
typical example is:
I make sure I have a ready supply ofconvenientfrzttyjbods on hand to take
with the Saquinavir. I teave my meds in the ldtchen for convenience, i.e.
cating with meds. I aiways carry at Ïeast 2 doses ofmy meds with me in case
I am ;iot convenientÏy close to home (ID 202)
Among “external sources” of planning, participants also reported using accessories
such as beepers, piilboxes or drug charts to remind them to take their medication.
2) Positive perception of medication
The second most cited category (36%) was “positive perception of medication”,
subdivided in three subcategories: “health benefits”, “positive attitude toward medication”,
and “few disadvantages ofmedication use”.
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“Health benefits” regrouped feedback provided from medical test about current
health status or improvements in health. Examples of these health benefits noticed by
participants are:
The great improvement in my health over the past iwo and a hafyears lias
,notivated me to take my medicution as prescribed (ID 203)
Drugs are working — higher T count /0 viral load — gives n?otivatïon when
deaÏing with drug skie eflècts (ID 204)
The ftzct that after being on meds Jr 3 menths my virai load went from
77 000 to undectectable and my CD4 went from 508 to 672 is the main
reason I take the meds (ID 205)
Having a “positive attitude toward medication” was also mentioned by participants:
Think positive thatpilts are workingfor you (ID 206)
I do ftel that when J get my resuits backfrom the doctor, and he says that my
counts are good and steady it makes me feeÏ that the meds are worldng (lie
way they shotdd (ID 207)
A few participants also mentioned that having only a “few disadvantages of
medication use” such as absence of side effects, easy regimen to follow, helped them
adhere to their regimens.
3) Social support
Twenty-five participants (33%) mentioned that emotional and practical stipport
provided by a significant person in their life helped them adhere to their regimens. Ywenty
four participants (32%) said that reminders or positive feedback from partner, close family,
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general social network or friends who arc themselves HIV-infected helped them adhere
to their medication regimens. Here are a few excerpts from patients’ answers:
As Jr people, having a ftw friends cail and asic if I have taken my meds
hetps sometime, especialiy ifI am feeling like I do iiot wish to take my meds
(ID 208)
Social support network teils me how great I ‘m looking — acts as an incentive
to continue HAART medication (ID 209).
A few participants (8 %) also mentioned support provided by medical staff as a
motivator to take their medication regularly.
4) Commïtment I Internai motivation
Some participants (2 1%) mentioned that being committed to take their medication
and using their “internal motivation” to do so help them adhere to their medication
regimens. However, the reason why a person was committed to take the medication was
reported as either positive or negative, with positive reasons being most ofien cited.
Positive reasons were centered on the desire to live; conversely negative reasons were
centcred on the fear of dying or suffering.
5) Seif-care
A few participants (15%) reported that general seif-care strategies such as rewarding
oneseif, using complementary therapies, having healthy living habits (e.g.: regular sleeping
schedule), or general improvement in their quality of life, helped them adhere to their
medication regimens.
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6) Research participation
Some participants (8%) indicated that participating in the current research helped
them adhere to their medication by providing tools, support or reminders to take the
medication.
7) Other answers
A few participants’ (11%) answers could flot be included in any of the categories
above and could not form a new category because of absence of a common theme between
them and!or low prevalence (e.g.: using certain type of food to help with swallowing puis).
Number of categories of facilitators mentioned
Most participants mentioncd using more than one category of strategy to facilitate
their adherence to medication. Among the 45% of participants who mcntioned only one
category, the most common answers were: using “planning skills” (62%), using “social
support” (15%) and having a “positive perception ofmedication” (12%). f ifty-five percent
of participants reported more than one category, with 28% reporting use of two different
categories of facilitators and 24% use of three to five different categories of facilitators.
Among participants who reported more than one category, the most common answers were:
using “planning skills” (76%), having a “positive perception of medication” (56%), and
using “social support” (49%) to facilitate adherence to medication.
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Facilitators and participants’ demographïc characteristics
Education level was significantly associated with “planning skills” (t(73) = -3.12, p
.003) and “positive perception of medication” (t(73) -2.23, p = .03): participants who
reported thcsc two categories generaÏly tended to have a higher education level than people
who did flot report them. No significant association was detected between education level
and the foilowing categories of facilitators: “social support” (t(73) .071, p = .94), “self
care” (t(73) = -1.38, p = .17) and “commitment / internai motivation” (t(73) = -1.37, p
1$)
Age of participants was significantly associated with “commitment / internai
motivation” (t(73) = -2.29, p = .03): participants who mentioned this category tended to be
older than participants who did flot mention it. No significant association was detected
between age and the following categories offacilitators: ‘planning skills” (t(73) = -.78, p
.044, “social support” (t(73) = -.44, p = .66), “seif-care” (t(73) -1.32, p = .19), “positive
perception ofmedication” (t(73) = -1.74, p = .09).
Impact of adherence intervention
Among $2 smdy participants, 10 were inciuded in an intervention program (MAX
HAART) during the one-year duration of the larger study because they had reportcd
adherence difficuities. No significant impact of treatment was noted when comparing
adherence results before and afier the intervention program for each of these individuals
(p= .06).
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facîlitators and adherence status
0f the 63 individuals included in the analyses, 30 (48%) were considered to have
suboptimal adherence to medication. No significant differences were detected in adhcrence
status (adherence vs. suboptimal adherence) between participants who mentioned one, two
and three to five categories of facilitators (x2 (2, N=63) 0.95, p = .62). There was also no
significant differences in adherence status detected between participants who mentioned or
did flot mention cach ofthe following categories: “planning skills” (X2 (1, N63) = 1.1 5, p
= .42), “positive perception ofmedication” (x2 (1, N=63) = 0.08, p = .80), “social support”
(x2(’ N63) = 1.15, p = .42), “commitment/intemal motivation” (x2 (1, N=63) 0.66, p =
.55), “self-care” (x2 (1, N=63) = 3.64, p = .09). See figure 1 (p. 119).
Discussion
Resuits from this study are consistent with previous research on reasons for
suboptimal adhcrcnce and facilitators of adherence. Interferences with daily routine were
the reasons most frequently mentioned by HTV-infected participants at their “worst” time of
adherence. However, one needs to be careftil when reporting reasons most frequently
mentioned by separating reasons that most frequently appeared as present and reasons that
happened most oficn. for example, “forgeuing”, which bas been reported as the most
prevalent reason for suboptimal adherence in the literature, was also found to be highly
prevaÏent when using a yes/no format of answer in this study, but was not as prevalent
when looking at how ftequently this reason interfered with medication taking. It is
interesting to note that most studies have either reportcd the presence or the absence of any
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given reason or have combined reasons that happened “often” with reasons that
happened “sometimes”, instead of focusing on those that happened “often” only.
Although the use of this ‘reasons’ questionnaire is interesting in that it helps to
describe the most common reasons for suboptimal adherence, it does flot inform us about
the context surrounding each reason. Some of these reasons might be determined by more
than one factor. This limits the type of conclusions we can generate from this data. for
example, forgetting could be causcd by several factors such as neurological factors or
distractions from daily routine.
Resuits from previous studies on some of the most comrnon types of facilitators of
adherence were also replicated. In descending order, facilitators of adherence mentioned by
at least 15 % of the participants were: (1) planning skills; (2) positive perception of
medication; (3) social support; (4) commitmentlintemal motivation; and (5) seif-care.
Grouping participants’ answers into these categories of facilitators has helped to inform us
about strategies and motivators of adherence behaviours that are commonly used by
participants in their day-to-day life.
A more thorough clinical understanding of adherence behaviours is obtained by
comparing facilitators of adherence with reasons reported for suboptimal adherence. The
adherence facilitator most often reported was “planning skills”, which is centered around
routine and integration of medication into activities of daily living. Because most of the
reasons for suboptimal adherence were centered on interferences with daily routine, the
category “planning skills” might be less efficient under a changing context if it is the sole
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strategy used to facilitate adherence. A recent study (Ryan & Wagner, 2003) found that a
routine for put taking is a critical component to successful adherence, and that peopic
whose lives werc more chaotic and less centered around routine wcre at a higher risk for
suboptimal adherence. These authors also pointed out the difficulty of using this strategy
under emotional stress or a changing context. As HIV-infected individuals regain better
health with medication, new challenges emerge as they return to a more active life, and
may thus need to adapt to disruptions in daily routine more ofien. This emphasizes the need
to rely on other types of strategies than just routine to remember to take medication.
Rates of suboptimal adherence reported in this study were comparable to rates
reported in other studies, but only a few studies have measured adherence over time
(Mannheimer et al., 2002; Sethi et al., 2003). The iack of association between adhercnce
status and the number of categories, as well as the type of category of facilitators could be
explained by several reasons. First, a higher number of categories of facilitators might not
necessary imply that these strategies or motivators are ail equally useftil and working
efficientiy. The number of categories of facilitators used might also reflect individual
differences: one type of category of facilitator might work by itself for someone, while
someone cisc might need to rely on several strategies to adhere successfully to his
treatments. The fact that no specific type of category was related to adherence could also be
expÏained by individual differences in preferences toward various kinds of strategies. In
fact, in our sample, the categories “planning skiils”’ and “positive perception of medication”
tended to be mentioned more often by participants with a higher education level.
Furthermore, the category ‘commitment/intemal motivation” tended to be reported more
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ofien by older participants. However, we might have flot been able to detect associations
between some of the category of facilitators and demographic characteristics because of the
smaÏler prevalence of participants who mentioned these categories (e.g., seif-care was
mentioned by only il individuals). The associations detected between type of facilitators
and participants’ demographic characteristics should be considered preliminary and will
need to be replicated with additional samples before generating any conclusion.
This study has also several limitations that limit the generalizability of the findings.
First, because of a seif-selection bias, our sample was flot completely representative of the
general poptilation of HIV-infected individuals (i.e. sample was comprised of mainly
Caucasian gay men). Participants excluded from the study sample were also different from
the final sample on two aspects: they tended to have a lower income and to report
intravenous drug use as a risk factor for HIV more often than individuals in the study
sample. Secondly, it is possible that adherence rate might have been biased by the use of a
self-reported scale, which usually tends to overestimate adherence. It was originally
plaimed to also measure adherence with Medication Event Monitoring Systems (MEMS)
for a sub-group of participants to validate self-reports, but participants refiised to use them
because of convenience issues. However, self-reported adherence questionnaires have bcen
found to be adequate adherence measures. They correlate with other measures of adherence
(Deeks, 2000; Duong et al., 2001; 1-Tugen et al., 2002), and they also predict therapeutic
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outcome, as measured by HIV RNA level ami CD4+ cell count (Mannheimer et al.,
2002; Walsh, Mandalia et al., 2002)
Ihirdly, the measure of facilitators was also limited in some ways. The question
might have been too broad to get at the core of the most important adherence facilitators. It
also did flot distinguish between motivators and strategies. Furthermore, there is the
possibility that its written format limited the information provided by flot allowing us to
probe participants’ answers to clarify them. finally, because time of administration of the
questionnaire on facilitators could flot be controlled for, the type of facilitators used might
have changcd through time. It would have been interesting to administer this question
several times to note if there were any changes in adherence facilitators mentioned through
time.
Despite these limitations, this study has several clinical implications. It informs us
about some of the most common types of facilitators used by a group of HIV-infected
individuals in their day-to-day lives. It replicates with a different group of subjects some of
the resuits obtained in two previous qualitative studies on facilitators of adherence. These
resuits also suggest the need to adapt adherence interventions to individual differences in
motivation and to reinforce efficient strategies already used by HW-infected individuals.
The more we leam about motivations underlying adherence to medication, the more Iikely
it is that we can intervene successfully with people who have adherence difficuities. It also
reminds health care providers of the importance of assessing each person’s adherence
facilitators to understand ail the underÏying factors that might contribute to adherent
99
behaviours. This study suggests that it might be usefiil for health care providers to also
ask patients what facilitates medication-taking to understand their day-to-day strategies
instead of focusing only on obstacles. Although exploratory, resuits of this study might also
indicate that the number or the types of adherence facilitators used by patients is flot
directly related to their efficacy in adhering to HAART. finally, this description of reasons
for missed medication doses and facilitators of medication taldng could also guide our
understanding of adherence behaviours, and inform future research efforts. It would be
interesting to study adherence facilitators in a more structured way by asking participants
about the most common types of strategies and motivations that they used to improve their
adherence behaviours in their day-to-day experience. It would also be interesting to explore
how these different adherence facilitators might interact together to improve adherence to
HAART.
Conclusion
Common reasons for suboptimal adherence and facilitators of adherence were
identified among a group of HW-infected individuals. Results from this study have clinical
implications. Knowledge about what impedes and facilitates adherence behaviours in
patients’ day-to-day lives can provide guidance for clinical practice. furthermore,
knowledge about individual differences in preferences toward various kinds of strategies
might help health care providers adapt their interventions to patients and to reinforce
efficient strategies already used by I-IIV-infectcd individuals in their day-to-day lives.
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Figure 1. Categories offacilitators by adherence status (N75)
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Table VII. Demographic Characteristics of Participants (N=82)
Characterïstic N % Mean (SD)
Age (years) 41.0 (7.2)
Education (years) 13.3 (2.3)
Monthly income ($) 1382.90 (972.3 1)
lime since tested HIV-positive (months) 99.4 (50.6)
Gender
Male 71 86.6
female 11 13.4
Race
Caucasian 66 20.5
Black 8 9.8
Other 6 7.3
Relationship status
Single 56 68.3
Living with partner 26 31.7
Work status
Working 66 80.5
Notworking 16 19.5
On long-term disability*
Yes 65 79.3
No 5 6.1
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Characteristic N Mean (SU)
Number of risk factors for HIV
Only one 66 80.5
More than one 14 17.1
Type ofrisk factor(s) for HIV
Same sex sexual contact 62 75.6
Heterosexual sexual contact 16 19.5
Intravenous drug use 11 13.4
Blood Transfusion 2 2.4
1993 CDC Classification (N=80)
Asymptomatic 15 18.3
Symptomatic 26 31.7
AIDS 39 47.6
Type ofmedication regimen
NRTI + PI 40 48.8
NRTI + NNRTI 24 29.3
NRTI+NNRTI+PI 15 18.3
3NRTIs 1 1.2
Viral load
Undetectable 39 47.6
Detectable:35 000 33 40.2
Detectable: > 35 000 8 9.8
*Missjng data n=12
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Table IX. Categories of adherence facilitators reported by participants (N75)
Categories N %
Planning skills 52 69.3
Positive perception ofmedication 27 36.0
Social support 25 33.3
Internai motivation 16 21.3
Seif-care 11 14.7
Research participation 6 8.0
Other answers $ 10.7
Table X. Types ofreasons reported for suboptimal adherence (N=42)
Didn’t want to take them
6 14.3
7 16.7
10 23.8
19 45.2
Could not find a place where no one
would sec you taking medicines
Oflen
Sometimes
Rarcly
Neyer
114
1 2.4
1 2.4
2.4
39 92.9
Ofien
Sometimes
Rarcly
Neyer
Was traveling/away from home
Often
Sometimes
Rarely
Neyer
Wasn’t feeling well
Often
Sometimes
Rarely
Neyer
Slept in Iate/went to bed early
Oflen
Sometimes
Rarely
Neyer
Feu asleep/slept through dose time
Often
Somctimes
Rarely
Neyer
Lost track oftime
Often
Sometimes
Rarely
Neyer
1-lad a change in daily routine
Oftcn
Somctimes
Rarely
Neyer
FeIt good
Oftcn
Sometimes
Rarely
Neyer
Forgol
Oftcn
Sometimes
Rarely
3 7.1
7 16.7
4 9,5
28 66.7
3 7.1
6 14.3
9 21.4
24 57.1
3 71
9 21.4
4 9.5
26 61.9
2 4.8
9 21.4
$ 19.0
23 54.8
2 4.8
6 14.3
9 21.4
25 59.5
2 4.8
8 19.0
5 11.9
2? 64.3
2 4.8
9 21.4
5 11.9
26 61.9
2 4.8
2 4.8
1 2.4
37 88.1
1 2.4
8 19.0
14 33.3
19 45.2
feIt depressed
Ollen
Sometimes
Rarely
Neyer
Could flot follow eating pattem required
by medication
Oflen
Sometimes
Rarely
Neyer
Feit drug was toxiclharmful 10 heallh
Oflen
Somelimes
Rarely
Neyer
Ran out ofpills
Oflen
Sometimes
Rarely
Neyer
Was having problems with side cftècts
Oflen
Sometimes
Rarely
Neyer
feit too tired
Oflen
Sometimes
Rarelv
Neyer
FeIt stressed out
Oflen
Sometimes
Rarely
Neyer
Had too many puIs to take
Often
Sometimes
Rarety
Neyer
1 2.4
2 4.8
5 11.9
34 81.0
1 2.4
3 7.1
2 4.8
36 85.7
1 2.4
3 7.1
O O
38 90.5
1 2.4
o o
1 2.4
40 95.2
O O
4 9.5
2 4.8
36 85.7
o o
11 26.2
3 7.1
28 66.?
O O
4 9.5
4 9.5
34 $1.0
o o
1 2.4
2 4.8
39 92.9
Busy with other things
Oflen
Sometimes
Rarely
Neyer
Reasons F 0/ Reasons F /0/0
Neyer
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Conclusion
The two articles included in this dissertation used complementary approaches with
the goal of improving the understanding of adherence behaviours. The first article focused
on behavioural prediction by studying risk factors for suboptimal adherence to HAART;
while the second article examined the day-to-day adherence process by exploring both the
reasons that might disrupt adherence behaviour at the most difficult time of adherence, and
the facilitators of adherence reported by participants. In the conclusion of this dissertation,
the main findings of both articles will be summarized and their clinical implications will be
presented. The theoretical implications of these findings will also be highlighted. Finally,
limitations and strengths of this dissertation will be addressed, and future research
directions will be suggested.
1. Main findings
Article 1
Twenty-seven individuals out of 68 (40%) reported at least one episode of
suboptimal HAART adherence over a period of 6 months. The impact of 8 potential risk
factors was tested with a logistic regression predicting suboptimal adherence to medication.
Results indicatcd that out of these 8 potential risk factors studied, the following 3 factors
were significantly associated with suboptimal adherence to HAART: alcohol use problems,
lower levels of confidence about the positive impact of HAART on health, and drug use
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problems. Resuits confirmed thrce of the initial hypotheses. With these three risk
factors, the overali proportion of individuals adequately classified across classes (adherence
vs. suboptimal adherence) in the current sample was 78%. Resuits ofthe logistic regression
indicated that the risk of suboptimal adherencc was 5 times ((CI): 1.2 — 21.3) higher in
participants who had a hazardous or harmful alcohol consumption and alcohol related
problems (e.g., guilt or remorse afier drinldng, injuring oneseif or someone else because of
drinking, etc.) compared to participants without such alcohol use problems. It also indicated
that for every one point increase in the degree of conlidence about medication efficacy
(measured with the HEXP1 questionnaire), the risk of having suboptimal adherence
decreased by 0.7 times in the sample (CI: 0.6 — 0.9). Therefore, participants who were more
confident about the positive impact of HAART on their health were less likely to have
suboptimal HAART adherence, and convcrsely participants who were more sceptical about
the positive impact of HAART on their health tended to be at increased risk for suboptimal
adherence. Also, participants who had drug use problems such as dependence on dnigs
(e.g., difficulty to stop using drugs, withdrawal symptoms) or serious consequences ofdrug
use in different life domains (e.g., interpersonal relationships, work difficulties, legal
problems) wcre found to be generally more likely to have suboptimal HAART adherence
than participants without such drug use problems. However, the impact of a drug use
problem on suboptimal adherence was flot as straightforward in the current sample: drug
use problem was significant in the overail mode! but the different !evels of drug use
prob!ems (e.g., low !evel, moderate !evel and substantia! to severe !eve! of problems) did
flot attain significance individually. As a resu!t, it was not possible to estimate the potentia!
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increasc in the level of risk due to a drug problem, nor discriminate the impact of
different levels ofdrug use problems on adherence. Finally, because ofthe large confidence
intervals in the odds ratio, estimates of the potential increase in the risk of suboptimal
adherence for these 3 risk factors should be seen as preliminary and will need to 5e
replicated in future studies.
f ive factors among the 8 potential risk factors studicd were flot significantly
associated with suboptimal adherence. Two of the initial hypotheses were confirmed:
suboptimal adherence was flot associated with demographic characteristics (age and
education), or severity of the disease (measured by disease staging). However, tbree of the
initial hypotheses were not con±irmed. $uboptimal adherence was unrelated to: (1) a greater
number of medical symptoms due to illness or side effects of medication; (2) a greater
number of depressive symptoms; and (3) both the positive and the negative impact of
medication use on daily ftinctioning (measured with the HEXP2 questionnaire).
Secondly, the association between participants’ beliefs about the positive impact of
HAART on their health (HEXP1 questionnaire) and their demographic, medical and
psychosocial characteristics was explored. Beliefs about medication efficacy were unrelated
to: demographic characteristics (age, gender, and education level), markers of disease
progression (such as viral load and hospitalization in the past 6 months), and the cognitive
sub-score at the depression inventory. Beliefs about HAART effect on hcalth werc fourni to
be related to: the number of medical symptoms and the severity of the disease (disease
staging). Participants with a greater number of medical symptoms due to illness or side
lis
cffects of medication tended to be more sceptical about the positive impact of HAART
on their heahh. Also, participants in the two following disease stages were found to have
significantly different beliefs about medication efficacy: participants with an AID$
diagnosis held more positive beliefs about the impact of HAART on their health than
people at the HIV symptomatic stage of the disease. However, the significance of this
relation was marginal (p=0.04) and the current sample size did flot allow for detection of
differences between these two stages and the asymptomatic stage of HIV. These resuits
should therefore be replicated in future studies before making firm conclusions.
Article 2
This exploratory study had for goal to describe both the barriers to and the
facilitators of adherence reported by HIV-infected individuals. The reasons most ofien
reported by participants (N=42) at their “worst” point of adherence over a one-year period
centered around interferences with daily routine. On the other hand, facilitators of
adherence reported by at least 15% of the participants (N=75) were classified into 5 main
categories (Iisted in descendïng order of frequency): (1) “planning skills”; (2) “positive
perception of medication”; (3) ‘social support”; (4) ‘commitmentfinterna1 motivation”; (5)
“self-care”. These categories were similar to resuits found in other studies on facilitators of
adherence (Remien et al., 2003; Roberts, 2000). Demographic characteristics of participants
who mentioned these different categories of adherence facilitators were explored. In the
present sample, participants who mentioned some of these facilitators shared a few
demographic characteristics in common. Participants who reported using p1anning skills”
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and a “positive perception of medication” to facilitate their adherence to FIÀART
tended to have higher levels of educational achievement than participants who did flot
mentioned these facilitators. Mso, participants who reported using “commitment/intemal
motivation” to facilitate their adherence to HAARY generally tended to be older than
individuals who did not mention this facilitator. Based on these associations it seems that
participants’ age and education level might influence the choice of adherence facilitator
reported in the current sample.
The relation between adherence status (adherence vs. suboptimal adherence) and the
number or the type of facilitators reported was also investigated. Among the 63 individuals
included in the analyses, 39 (48%) had suboptimal adherence when measured over a period
of one year (360 days). No significant association was found bctween adherence status and
the number or the types of category of facilitators mentioned by participants. However,
because of the exploratoiy nature of this study these relations will need to be replicated
before one can make definite conclusions about them.
2. Clinical implications
Rates of suboptimal adherence found in both articles were comparable to resuits
obtained in the few studies that have measured adherence over time (Mannheimer et al.,
2002; Sethi et al.. 2003). Because most HW studies have assesscd adherence over the past
week or the past few days, this dissertation provides additional clinical information on
adherence to HAART over longer periods of time.
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This dissertation was also able to identify important risk factors for suboptimal
adherence to HAART that need to be explored in clinical practice. It highiighted the need to
monitor for hazardous or hannful alcohol consumption and alcohol related problems (e.g.,
guilt or remorse afier drinldng, injuring onescif or someone cisc because of drinking, etc.)
as they represent clear risk factors for suboptimal adherence to HAART. it also suggested
that drug dependence or serious consequences of drug use on different life domains can
potentiaily increase the risk for suboptimai adherence to J-IAART. Thcrefore, these resuits
indicated that substance use that negatively affected different life domains within the past
year increased the risk of suboptimal HAART adherence. Social instability, which is part of
a substance abuse diagnosis based on the DSM-IV criteria, may be important to considcr in
clinical practice. In fact, an earlier study (Boulmik et al., 2002) found that even former dnig
users who met the criteria for social instabiiity were at incrcascd risk for suboptimal
adherence. Considering these findings, it would bc important to screen for substances use
problems and serious consequences of substance use while discussing adherence to
HAART. It might be necessary to concurrently treat substance use problems and to provide
concrete help with consequences associated with substance use in order to improve
adherence to HÀART when these treatments are initiated.
Resuits of both articles included in this dissertation highlighted thc necd to ask
patients about their beliefs conceming the impact of HAARI on their hcalth status. In fact,
having a “positive perception of medication” was frequently mentioned as a facilitating
factor for HAART adherence in the second article of this dissertation. It was also found in
the first article of this dissertation that participants who were more confident about the
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positive impact of HAART on their health were less Iikely to have suboptimal
adherence to HAART. However, beliefs about the positive or the negative impact of
HAART on daily ftinctioning did flot appear to have such a direct impact on adherence.
The lack of association between suboptimal adherence and demographic
characteristics or severity of the disease (measured by disease staging) highlighted again
the dynamic nature of adherence to treatment. In fact, adherence is flot a “static”
phenomenon and is seldom associated with stable patients’ characteristics, but usually
changes through time for a given individual. The fact that a greater number of depressive
symptoms was flot significantly associated with suboptimal adherence was surprising as
depressive symptoms are ofien reported as risk factors for suboptimal adherence
(Ammassari et al., 2004; DiMatteo et al., 2000; Gordillo et al., 1999; Hoizemer et al., 1999;
Starace et al., 2002). This lack of association should be interpreted carefully as it might be
explained by the low prevalence of depression in the current sample, and by the type of
measure used. Because the total score at the depression inventory included medical
symptoms, the cognitive sub-score was used for the analyses. This score might flot have
been sensitive enough to detect depressive affect in the current medical sample. It was also
surprising to note the lack of association between suboptimal adherence and number of
medical symptoms due to illness or side effects of medication because they have ofien been
reported as risk factors for suboptimal HAART adherence (Ammassari et al., 2001;
Hoizemer et al., 1999; Trotta et al., 2002; Wagner, 2002). However, this Iack of association
should also be interpreted carefiilly as it might partly be explained by the fact that the
population studied here rcported a relatively low number of medical symptoms.
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Furthermore, the questionnaire did not distinguish between symptoms of 111V and side
effects of medication and the different types of medical symptoms reported by participants
were flot taken into consideration. It would be expected that gastrointestinal symptoms such
nauseaJvomiting, which are usually more bothersome and arc among the principal causes of
medication discontinuation (OtBrien et al., 2003), would have a stronger impact on
adherence. Also, the symptoms covered by the questionnaire might flot have been
representative of the most bothersome symptoms (for example, diarrhea was flot included
in the list ofsymptoms).
This dissertation also provided some insight into factors that might be associated
with more scepticism about the positive impact of HAART on health status (beliefs about
medication efficacy). This exploration of factors associated with scepticism about
medication efficacy has important clinical implications since these beliefs about medication
efficacy were significantly associated with suboptimal adherence to HAART. The fact that
positive beliefs about medication tended to decrease as the number of medical symptoms
due to illness or side effects of medication increased is clinically important. Another
clinically important association was noted between beliefs about medication and severity of
the disease (disease staging): people with an AID$ diagnosis held more positive beliefs
about their medication than people at the mildly symptomatic stage. Theses resuits are
interesting because both the number of medical symptoms due to illness or side effects of
medication and the severity of the disease were not directly related to HÀART adherence,
but seem to be indirectly associated to adherence by their impact on participants’ beliefs
about HAART effect on their health. This finding that participants seemed to be more
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sceptical about HAART effect on their health as their number of medical symptoms
increased raised an interesting question: could beliefs about medication efficacy be partly
based on the number of medical symptoms people are experiencing? Since number of
medical symptoms seemed to influence beliefs about medication, this distinction between
AIDS and symptomatic stage was also interesting because this might mean that people
interpret differently the symptoms that they have as they are diagnosed with AIDS. For
those individuals with an AIDS diagnosis, symptoms might be perceived accurately as a
progression of the disease, because they are more serious and can directly be associated
with AIDS. In contrast, those at the mïldly symptomatic stage might misread less serious
symptoms as side effects of medication. These hypotheses would need to be tested further
before making firm conclusions. However, if these associations were founded, this might
emphasize the need for health care providers to be aware of a possibility to misaftribute
symptoms due to illness progression as side effects of medication in the mildly
symptomatic stage.
The lack of association between participants’ beliefs about the impact of HAART
on their health and important markers of disease progression, such as viral load and having
been hospitalized in the past 6 months found in the first article was surprising. This might
indicate that people’s beliefs about the effect of medication on their health are less related
to the clinical reality, and more a function of their own perception. This resuit was
surprising because this seemed to contradict resuits of the second article in which several
participants mentioned that receiving feedback from medical test helped them to better
adhere to I-IAART by improving their “positive perception of medication”. However, the
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lack of association found in the first article could also be explained by the fact that our
measure of viral load was flot necessarily taken at the same time as people fihled the beliefs
questionnaire since it was taken from their most recent medical exam. Therefore, their
clinical status might have bcen somewhat different when they fihled the belief
questionnaire. Nonetheless, health care provider should be aware that beliefs about
medication efficacy may flot aiways reflect the clinical reality of patients and represent
instead patients’ prior beliefs about medication. It might then be useful to confront theses
perceptions with clinical reality (improvements in viral load, CD4 counts, etc.) and to
empliasize regularly to patients any progress in health status that could be attributed to
medication use.
Exploring other facilitators of adherence mentioned by participants also gave us a
clearer idea of the type of day-to-day strategies and motivators that they use to facilitatc
their adherence to HAART. Knowing what type of strategies HW-infected individuals use
or what motivates them to take their medication in their day-to-day lives may help health
care providers tailor their strategies of communication to each individual so as to
emphasize the need for strict adherence. It might also be useful to explore the clinical utility
of capitalizing on strategies or motivators already adoptcd by participants in this study such
as: internai or external sources of planning. having a globally positive perception of
medication use, the use of close social support, making a commitment or using internai
motivation, and using self-care strategies.
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In addition, comparing reasons for suboptimal adherence to facilitators of
adherence raised questions about the use of “planning sldlÏs”, centered on routine and
integration of medication into activities of daily living, as the sole strategy to facilitate
adherence. Because reasons for suboptimal adherence at the “worst” adherence time point
concerned interferences with daily routine, the use of “planning skills” might flot be
optimal under a changing context. for example, as HIV-infected individuals regain better
health with medication, new challenges emerge as they retum to a more active life and have
to adapt to disruptions in daily routine on a frequent and unpredictable basis.
The lack of association between adherence status and number or types of facilitators
mentioned confirms clinical observations about the complexity of the adherence
phenomenon and the individual differences in how to deal with challenges raised by
adherence. This could reflcct individual preferences toward various kinds of strategies: one
type of facilitator might be sufficient on its own for someone, while someone else might
need to rely on several facilitators to adhere successftilly to his treatments. Exploratory
analyses showed that the choice of facilitators tended to be associated with certain
participants’ characteristics. Based on these preliminary results, health care providers might
want to keep in mmd patients’ characteristics and lifestyle when providing guidance about
useful strategies that could improve adherence. This highlights again the importance of
listening to patients’ stories, and to try to understand their perceptions about medication to
have a better grasp at their decision making process. It is even more important to carefully
listen to patients given the inherent difficulty of adhering to HAART regimens because of
their stringent demands and their impact on quality of life (e.g., side effects).
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3 Theoretîcal implications
Resuits of both of these articles can provide a better theoretical understanding of
adherence behaviours in the context of HAART regimens. Similar to the present studies,
much of research in the field of HW uses an atheoretical approach to study factors
associated with suboptimal adherence to medication. Because the two studies included in
this dissertation were mainly exploratory, an atheoretical approacli offered the advantage of
identifying, based on prior studies, a subset of participants’ factors that might impact
adherence in the current sample. Contrary to other atheoretical approaches that focused on
stable patients’ characteristics, most of the participants’ characteristics studied in article I
(especially depressive symptoms, beliefs about medication efficacy, substance use
problems) were amenable to change. These factors were chosen based on the fact that
adherence is flot a “static’ or ‘trait” phenomenon and usually varies over time for the saine
person. Using an atheoretical approach also provided the opportunity to explore new
concepts such as beliefs about medication efficacy in order to generate theories or increase
our understanding of adherence behaviours.
3.1 Conceptualization of belïefs about medication
Implications for the conceptualization of the types of beliefs that might impact
adherence are provided by thc resuits of the first article included in this dissertation:
participants’ beliefs about the positive impact of HÀART on their health (HEXPI
questiormaire) were associated with suboptimal adherence, while beliefs about the positive
or negative impact of HAART on daily functioning (HEXP2 questionnaire) were not
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associated with adherence. These questionnaires appeared to meastire two different
theoretical concepts: the first questionnaire was centered on global beliefs about medication
effect on health, while the second referred to quaÏity of life issues and expectations about
the positive or the negative impact of medication use on daily functioning. Therefore, it
seems that global beliefs about medication effect on health directly impact adherence to
treatment, while medication impact on functioning or quality of life may have a less direct
influence on adherence. However, the strong correlation between these two questionnaires
showed the complementary aspect of both concepts. In fact, global functioning is one
aspect that influences the type of beliefs a person holds about medication effect on her
health. However, the smaller correlation between beliefs about the positive impact of
HAART on health (HEXP1) and beliefs about the negative impact of HAART on daily
functioning (HEXP2 negative scale), compared to the positive impact of FTAART on
functioning, may indicate that people’s global beliefs about medication effect on health are
more strongly affccted by the positive impact rather than the negative impact of medication
on daily functioning. The second article included in this dissertation also provided a better
understanding of factors that influenced “positive perception medication”. These
conceptual distinctions in types of beliefs about medication efficacy associated with
HAART adherence behaviours are important and might need to be distinguished further. It
would, in fact, be interesting to distinguish between other types of beliefs that have
previously been associated with medication use in other ilinesses such as: long-term
dangers, danger of medication because of its chemical nature, addiction and dependence,
and medicine perceived as a poison (Home, 1997).
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3.2 Theoretical models
Some of the resuits that emerged in the two articles included in this dissertation
point to additional research avenues and may be understood within the context of existing
theories. Given that being more skeptical about the positive impact of HAART on health
represents a risk factor for suboptimal adherence, and that more skepticism about FLAÀRT
efficacy is associated with a greater number of medical symptoms due to illness or side
effects of medication, one might suggest that the number of medical symptoms may
indirectly affect adherence by influencing patients’ beliefs. Furthermore, beliefs about
HAART efficacy also seemed to be associated with disease stage: patients with an AID$
diagnosis tended to have more positive beliefs about HAART impact on their health than
patients at the symptomatic stage of the disease. As exposed earlier, because the number of
medical symptoms seemed to influence beliefs about medication, this distinction between
AIDS and symptomatic stage might mean that people interpret differently the symptoms
that they have as they are diagnosed with AIDS. For those individuals with an AIDS
diagnosis, symptoms may be perceived accurateÏy as a progression of the disease, because
they are more serious and can directly be associated with AIDS. In contrast, those at the
mildly symptomatic stage might misread less serious symptoms as side effects of
medication. It would be interesting to test these preliminary hypotheses regarding
symptoms representation within a Self Regulatory Mode! oflllness (Leventhal et al., 1992).
The Self Regulatory Mode! of T!lness (SRMI, sec Figure 2, p. 137) implies that
health-behaviours are the equivalent of coping responses that are influenced by patients’
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beliefs about their illness. It emphasizes the impact of concrete symptom experience in
producing representations of illness and guiding the coping response (coping = adherence
in the current context). This assumes that individuals’ attempts to comprehend and cope
with illness are guided by implicit and personal cognitive, as well as emotional
representation of iliness structured around 5 themes: identity, cause, timeline, consequences
and cure/control. Treatment beliefs were recently added to this model by a different author
(Home, 1997). It is believed that representation of treatment or medication will follow the
same process as illness representation with symptoms representations influencing beliefs
about medication efficacy. The association between beliefs about medication efficacy and
adherence, as well as beliefs about medication efficacy and number of medical symptoms
due to illness or side effects of medication found in the first article of this dissertation seem
to support the importance of the subjective symptom experience in guiding representation
of medication and finally adherence (seen here as a coping strategy). Ibis was also outlined
in the second article of this dissertation with some participants stating that by perceiving
changes in their health status, they believed that the medication was working as it should.
In the same une, Cioffi’s Somatic-Perceptual Mode! (SPM, sec figure 3, p. 138)
states that a perccived or inferred somatic change can initiate an interpretative process that
creates an internai representations of the symptom which can then be mediated by factors
such as: affect, motivation, gencral disposition, as well as prior hypotheses about this
symptom, to eventually produce a given behaviour (Cioffi, 1991).
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The problem with both of these models ($RMI and $PM) is that their
complexity renders them difficuit to test in clinical settings. Very few studies have used thïs
approach in the HIV literature. Resuits of one recent study (Johnson, Stallworth, &
Neilands, 2003) suggested that most HIV-infected individuals made causality attributions
regarding physical symptoms expcrienced and that these attributions varied widely across
individuals and physical complaints. This study also found that patients made their own
distinctions between symptoms ofthc disease and side effects ofmedication.
The second article of this dissertation highlighted important strategies or motivators
of adherence behaviours in patients’ day-to-day reality, regrouped in categories of
adherence facilitators. It is interesting to note that some of the categories of facilitators
identffied in this second article, namely: “planning skills”, “positive perception of
medication”, “social support”, “commitmentlintemal motivation”, reflected some of the 8
key elements of behavioural performance that were identified across the following 5
theoretical models: Health Belief Mode!, Social Cognitive Theory, Theory of Reasoned
Action, Theory of seif-regulation, Theory of subjective Culture and Interpersonal relations
(fishbein et al., 2001). The 8 following key elements of behavioural performance were
identified by the committce composed of the experts who created cach of these 5 theoretical
models: (1) a positive intention to perform the behaviour, (2) the Iack of environmental
constraints that interfere with the behaviour, (3) necessary skills to perform the behaviour,
(4) positive anticipated outcomes of perfonning the behaviour (or positive attitude), (5)
normative pressure to perform the behaviour, (6) self-standards: the behaviour is consistent
with self-image, (7) emotional reaction to performing the behaviour is more positive than
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negative, and (8) belief in the capacity of performing the behaviour (self-efficacy).
Therefore, a more in depth study of adhercnce facilitators might help provide additional
information on key aspects of adherence behaviours by providing guidelines for further
theoretical development.
3.3 Conceptualization of “adherence”
The questionnaire used to describe the most common reasons for suboptimal
adherence (included in the second article of this dissertation) highlighted the need for a
better operationalization of the tcrm “suboptimal adherence” by taldng into consideration
the different motivations that might underlie such adherence difficulties. Because these
reasons were flot conceptually regrouped and could have been determined by more than one
factor, the types of conclusions that could be generated from this data were limited. For
example, forgetting could be caused by several factors such as neurological factors or
distractions from daily routine. Therefore, in addition to the inherent difficulties associated
with adherence measurement that were discussed in the introduction of this dissertation, an
added complexity to this field of research is to adequately conceptualize the term
“adherence”. “Adherence” is often flot operationalized clearly in the current literature and
ftequently regroups different types of adhcrence behaviours. For example, a distinction can
be made between unintentional and intention non-adherence. Home (Home, 1997) defines
unintentional non-adherence as: non-adherence that happens when the patient’ s intentions
are hindered by barriers such as forgetting, inability to follow treatment because of poor
understanding, or physical problems such as poor eyesight. Intentional non-adherence is
132
defined as: non-adherence that is deliberate or intentional and happens when the
patient’s actively decides to flot folÏow his treatment as instructed. It might also be
beneficial to distinguish between consistent seif-tailoring of regimen that does not folÏow
medical advice, and intentional non-adherence that resuits in skipping doses once in a
while, as they might be generated by different types of motivations and might flot be
comparable. By regrouping different kinds of adherence behaviour we are in fact studying
different concepts which could explain the divergent resuits found in the literature on the
influence of several aspects such as demographic characteristics, as well as other
psychological characteristics on adherence to medication.
4. Limitations
Both studjes included in this dissertation have limitations that affect the
generalizability of the findings. firstly, like most studies that explored adherence to
medication over the long term, the current sample of participants might flot have been
representative of the general HIV-infected population because they “adhered” to a year
long study. Secondly, people who dropped out or were excluded from our sample were
significantly different from the final sample on Pvo aspects: they tended to have a lower
income and to report intravenous drug use as a risk factor for HW-infection more often
than individuals in the study sample. Third, the sample was mainly composed of Caucasian
gay men. It was also possible that the adherence rate might have been biased by the use of
self-reported scale, which usually tends to overestimate adherence rates. Tt was originally
planned to use MEMS caps with a subgroup of participants but they refused to use them
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because of convenience issues. However, self-reported adherence questionnaires have
been found to provide adequate adherence measures because of their correlation with other
adherence measures (Deeks, 2000; Duong et al., 2001; Hugen et al., 2002) and their ability
to predict therapeutic outcomc, as measured by HIV RNA level and CD4+ ccli counts
(Mannheimer et al., 2002; Walsh, Mandalia et al., 2002).
Because of the study design, it was flot possible to control for several variables such
as: changes in medication regimens over time, time since tested HIV-positive, and type of
medication taken (various HAART regirnens). The fact that HAART medication regimens
were flot identical might also have influenced the resuits of this dissertation, as different
types of medication corne with more or iess bothersorne side effects and have different
impacts on fiinctioning. However, because this study was flot based on a clinical trial and
used a convenience sample it was flot possible to control the type of HAART medication
taken given the variability of medication combinations available for patients. The measure
of adherence facilitators was aiso limited by the design of this rescarch which did flot ailow
to control for time of administration (the measure was taken at different tirne intervals from
baseline). However, the resuits at the Adherence Facilitators Questionnaire should be
relatively stable over a period of several rnonths because participants in the study had been
taking medication for a few years and were being asked what generally helped them adhere
to FLkART. It can be reasonably postulated that these ïndividuals had developed a set of
habits and/or strategies to facilitate adherence. In addition, the question that probed about
participants’ adherence facilitators might have been too broad and did flot distinguish
adequately between strategies and motivators of adherence. Aiso, its written format did not
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allow to clarify participants’ answers. finally, the current sample size may have
affected the ability to detect smaller associations, and did flot allow a clear estimate of the
impact of each risk factor for suboptimal adherence in the first article of this dissertation.
5 Strengths
The main strength of this dissertation is the use of both a quantitative and a
qualitative methodology to gain a better understanding of adherence behaviours.
Medication adherence was also measured longitudinally over periods of approximately 6
months to 1 year. This is veiy uncommon in HIV research given the inherent difficulties of
following patients over long periods of time. In fact, adherence behaviours are ofien only
measured over the past few days in most ofthe HIV literature.
This dissertation replicated previous results and identified important risk factors for
suboptimal adherence. This dissertation also explorcd a newly developing area of
adherence behaviour research: beliefs about HAART efficacy. Even if the resuits of this
dissertation should be considered exploratory, they provided some guidelines for clinical
practice as well as for further theoretical conceptualization of adherence behaviours. This
dissertation also added a complemcntary perspective to the field of HW medication
adherence by looking at both sides of adherence behaviours: what impedes and what
facilitates adherence to HÀART as expressed by HIV-infected individuals. In this regard, it
has the strength of listening to what participants’ bclieve is helpful and including their
perspective on HAART adherence. Most of the adherence studies, while providing
135
additionaÏ information about patient’s behaviours, limited their focus on obstacles or
barriers to adherence. As such, it is interesting to study the other side of the problem by
also exploring facilitators of adherence. Focussing on strategies or motivators of adherence
already used effectively by patients in their day-to-day lives may bring a more positive
outlook in thïs field. It might also empower patients by taking into consideration their daily
efforts aiid struggies with adhering to HAART regimens. It also has the added advantage of
giving a voice to patients in a field where it has often been neglected.
6. Future directions
Several avenues are left to be explored to better understand adherence behaviour as
it pertains to the field of HIV researcli. Definition and measurement of adherence have to
be studied further. It wilI be important to define the concept of “adherence” more precisely
in order to distinguish betwcen types of suboptimal adherence that might be conceptually
different (e.g.: intentional non-adherence vs. unintentïonal non-adherence). A better
operationalization of the term “adherence” may bring more clarity to this field of rcsearch.
It wiIl also become essential to improve adherence measurement in order to obtain more
consistent results.
As it is important to use atheoretical approaches to explore new avenues in regard to
factors associated with adherence. it is as important to understand the underlying reasons
why a factor may interfere with adherence within existing theories. Therefore, there is a
need for sound theory-based research in the field of HIV medication adherence.
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It would also be interesting to study the meaning of T-TAART medication in
patients’ life and to explore more thoroughly patients’ beliefs about the efficacy of
HAÀRT. In order to have a more complete conceptual understanding of beliefs about
medication efficacy, these beliefs would need to be studied in a longitudinal design to see if
they fluctuate and to measure their impact on HAART adherence over time. It will be
essential to combine research and clinical intervention studies in order to generate clearer
guidelines on how to help HIV-infected individuals handie such challenging medication
regimens on a day-to-day basis over long periods oftime.
Individuals taldng HAART regimens have difficuit living conditions which need to
be taken into consideration while providing support for UAART adherence. It is also
important to keep in mmd that these regimens might be perceived as a constant reminder of
the ‘sick role” identity. In this context, it will be essential to study more thoroughly the
likely ambivalence patients have about taking medication that will help them live longer,
but wiII negatively affect other spheres of their life and ofien produce distressing sidc
effects. In this regard, studying both sides of the decision making process regarding
adherence to HAART is essential in order to get a better understanding of patients’
ambivalence toward medication use. Could exploring both side of the decision making
process bring a better understanding of patients’ representations of HAART and help us
understand how these regimens are integrated into patients’ identify?
Figure 2. Self Regulation Model (adapted ftom Leventhal, 1992)
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Annex A :Questionnaires
J
DEMOI
dU - mon - year eval#
HAART Adherence n HV Infectbn Project
BachelorD MastersD PhDD MDD JDD
Diploma obtained:
___
___
___
___
___
___
_
CURRENT EMPLOYMENT
STATUS
VolunteerD
#hourslweek
If flot currently employed
when Uid you work Iast
MEDICATION
PAYMENT PLAN
(check ail that apply)
Monthly Payments for
HIV medications (typical)
Monthly Income (typical)
SOURCE 0F INCOME
(check ail that apply)
empioymentD
perso na
paid fuIl-timeD paid part-timeD#hours!week_
self-employed tuii-timeD self-employed part-time D#hourslweek
unempioyeuD studentD retireD longterm disabilityD
dU - mon - year How long on disability?
years
privatelgroup insuranceD %coverage_____
Trillium planD ODSP (Family Benefits)D HomecareD
Social Assistance (Welfare)D Personallhousehold incomeD
Personal savings
D OtherD
___
___
$____________
$____________
Iong-term disabilityD Canada pension plan disabilityD
support from friendslfamilyD ODSP(Family Benefits)D
social assistance (welfare)D OtherD____________________
How did you find out about this study?
(or who referred you?)_________________
Date of Birth: (dd-mon-year)_ - _-_Age_
Gender male D
femaleD
transgenderD
EDUCATION
The highest grade level obtained in school: Total number of years in school_________ yeats
grades O to BD grades 9 to II D grades 9 to 12D Received high school diploma? YesD
NoC
Years cf university or college completed:
ID 20 3040 5ormoreD
_
RELATIONS H IP
STATUS
singieD marriedD
common-iawD living with partnerD
separatedldivorced D
partnerlspouse dieU D
DEMOI id#
dU - mon - year eval#
HAART Adherence in HV nfection Project
savings D
Number of dependents: NoneD How many?______
DEMO2 id#
HAART Adherence in HIV Infection Project ud-mon-year eval#
What is your birthplace? Country_____________ If flot Canada then how long in Canada? years
What is your mother’s birthplace?Country_____________ If not Canada then how long in Canada?
What is your father’s birthplace? Country_____________ If flot Canada then how long in Canada? years
When you were growing up as Where was this? Country_____________________
a child, what language(s) did
you speak?
At what age did you first learn Do you consider yourself fluent in NoC
to speak English? English? Yeso
Do you have any religious or NoC Yes yes, what is the religion?
spiritual affiliation?
What is your current sexual gays heterosexual bisexualD lesbianD othercJ
orientation?
Are you involved in community activities? No Yesc If yes, how would you describe the community?
(meetings, festivities, fundraising, advocacy)
IMM1 id#
dd - mon - year visit#
HAART Adherence in HIV Infection Project
This is your indivïdualized medïcation monitor.
(C:.DAT revised on December 12, 2001)
The foilowing should be an accurate description of the medicines currently prescribed by your doctor:
l5Omg 3TC: 1 white diamond pill twice per day.
4Omg d4T: 1 brown piil twice per day.
400mg Crixivan: 2 white and green puis twice per day.
iOOtrtg ritonavir: 2 beige puis twice per day.
If this is NOT correct, ask your HAART project contact person to create a new up-to-date individualized
medication monitor for you and do not complete this outdated foi-m.
CIRCLE ail appropriate answers. 1f you can’t remember, give your best estimate. If that is not
possible, circle the question mark at the end ofthe hne so that ail unes are marked with one circle.
Think about yesterday.
Day ofthe week(circie one): [MON TUE WED THU FR1 SAT STJN)
How many times did you take the white diamond piil none once twice 3x 4x ?
How rnany times did you take the brown pili none once twice 3x 4x ?
How many times did you take botli 0f the 2 white and green pills none once hvice 3x 4x ?
How many times did you take only 00e 0f the 2 white and green pille none once hvice 3x 4x ?
How many times did you take both cf the 2 beige pille none once twice 3x 4x ?
How many times did you take only one 0f the 2 beige pille none once Pvice 3x 4x ?
Think about tite duy before yesterday (2days ago).
Day of the week(circie one): [MON TUE WED THU FR1 SAT SUN]
How many times did you take the white diamond piil none once hvice 3x 4x ?
How many times did you take the brown pili none once hvice 3x 4x ?
How rnany times did you take both cf the 2 white and green puis none once twice 3x 4x ?
How rnany tirnes did you take only one cf the 2 white and green pille none once twice 3x 4x ?
How rnany times did you take both of the 2 beige puis none once twice 3x 4x ?
IMM2 id#
dd - mon - year visit#
[ART Adherence in HIV Infection Project
How many times did you take only one cf the 2 beige pille none once bvice 3x 4x ?
Tltiîtk about your actvities 3 days ago.
Day ofthe week(circle one): [MON TUE WED THU FR1 SAT SUN]
How many times did you take the white diamond pili none once twice 3x 4x ?
How many times did you take the brown pill none once twice 3x 4x ?
How many times did you take both of the 2 white and green pille none once hvice 3x 4x ?
How many times did you take only one 0f the 2 white and green pille none once hvice 3x 4x ?
How rnany times did you take both cf the 2 beige puis none once twice 3x 4x ?
How many tirnes did you take oniy one cf the 2 beige pille none once bvice 3x 4x ?
Think about your actvities 4 days ago.
Day of the week(circle one): [MON TUE WED THU FR1 SAT SUN]
How many times did you take the white diatncnd pill none once hvice 3x 4x ?
How many times did you take the brown pili none once Pvice 3x 4x ?
How many times did you take both of the 2 white and green pills none once twice 3x 4x ?
How many times did you take only one cf the 2 white and green pille none once twice 3x 4x ?
Howmanytimesdidyoutakeboth cf the 2 beige piils none once hvice 3x 4x ?
How many times did you take only one 0f the 2 beige pille none once twice 3x 4x ?
Think about your actvities S days ago.
Day of the week(circle one): [MON TUE WED THU FR1 SAT SIJN]
How rnany times did you take the white diamond pill none once twice 3x 4x ?
How many times did you take the brown pili none once hvice 3x 4x ?
How many times did you take both of the 2 white and green pille none once hvice 3x 4x ?
How many tirnes did you take only one of the 2 white and green pille none once hvice 3x 4x ?
How rnany tirnes did you take both 0f die 2 beige pille none once twice 3x 4x ?
How many times did you take only one of the 2 beige pille none once twice 3x 4x ?
IMM3 id#
dd
- mon - year visit
[!LAART Adherence in HIV Infection Project
Think about your actvities 6 days ago.
Day of the week(circle one): [MON TUE WED THU FR1 SAT SUN]
How many times did you take the white diamond pili none once twice 3x 4x ?
How many times did you take the brown pili none once hvice 3x 4x ?
How many times did you take both 0f the 2 white and green puis none once hvice 3x 4x ?
How many times did you take only one 0f tIse 2 white and green puis none once hvice 3x 4x ?
How many times did you take both 0f tIse 2 beige puis none once hvice 3x 4x ?
How many times did you take only one of the 2 beige puis none once hvice 3x 4x ?
Think about your actvities 7 days (a week) ago.
Day ofthe week(circle one): [MON TUE WED THU FR1 SAT SUN]
How many times did you take tIse white diamond pili none once hvice 3x 4x ?
How many times did you take tIse brown piil none once bvice 3x 4x ?
How many times did you take both of the 2 white and green puis none once twice 3x 4x ?
How many times did you take only 0fl5 0f tIse 2 white and green piils none once hvice 3x 4x ?
How rnany times did you take both 0f tIse 2 beige puis none once twice 3x 4x ?
How many times did you take only one 0f tIse 2 beige puis none once bvice 3x 4x ?
nstructions: This questionnaire consists of 21 groups of statements. Please read each group of
statements carefully, and then pick out the one statement in each group that best describes the way you have
been feeHng during the past two weeks, including today. Check (f) the box beside the statement that you
have picked. If several statements in the group apply equally well, check off the highest number for that group.
Make sure to read ail statements in each group before marking a statement.
Place one and only one check (f) in each group.
1. Sadness
00 do notfeelsad.
I feel sad much of the time.
20 I am sad ail the time.
30 I am so sad or unhappy that I cant stand it.
2. Pessimism
00 I am flot discouraged about my future.
I feel more discouraged about my future than I
used to be.
20 I do flot expect things to work out for me.
3D I feel my future is hopeless and will only get worse
3. Past Failure
oc I do notfeel like a failure.
10 I have failed more than I should have.
20 As I look back, I see a lot offailures.
3D I feel I am e total failure as a person.
4. Loss of Pleasure
Oc I get as much pleasure as I ever did from
the things I enjoy.
10 I dont enjoy things as much as I used to.
I get very little pleasure from the things I used to enjoy.
30 I can’t get any pleasure from the things I used to enjoy.
5. Guilty Feelings
Oc I dont feel particularly guilty.
10 I feel guilty over many things I have done
or should have done.
20 I feel quite guilty most of the time.
3D I feel guilty ail of the time
6. Punishment Feelings
00 I dont feel I am being punished.
10 I feel I may be punished.
20 I expect to be punished.
3D I feel I am being punished.
7. SeIf-Dislike
00 I feel the same about myself as ever.
10 I have Iost confidence in myself.
20 I am disappointed in myself.
3D I dislike myself.
8. Self-Criticalness
00 I dont criticize or blame myself more than usuel.
10 I am more critical of myseif than I used to be.
20 I criticize myself for ail of my faults.
301 blame myself for everything badthat happens.
9. SuicidaI Thoughts or Wishes
00 I don’t have any thoughts of killing myself.
10 I have thoughts of killing myself, but I
would not carry them out.
20 1 would Iik fn khi myself.
3D I would kiIl myself if I had the chance.
10. Crying
00 I don’t cry anymore than I used to.
10 I cry more than I used to.
20 I cry over every little thing.
30 I feel like crying, but I can’t.
CONTINUED ON NEXT PAGE!
11. Agitation
00 I am no more restless or wound up than usual.
10 I feel more restless or wound up than usual.
20 am so restiess or agitated that its hard to stay stHl.
30 I am so restless or agitated that I have to keep moving
or doing something.
12. Loss of lnterest
00 I have not iost interest in other people or activities.
10 I am Iess interested in other people or things than before.
20 have Iost most cf my interest in other people or things.
30 it’s hard to get interested in anything.
13. lndecisiveness
00 I make decisions about as weH as ever.
10 I find t more difficuit to make decisions than usual.
20 have much greater difficuity in making decisions
than used to.
30 have trouble making any decisions.
14. Worthlessness
00 I do not feel I am worthless.
10 I don’t consider myself as worthwhile
and useful as I used to.
20 I feel more worthless as compared to other people.
30 I feel utterly worthless.
5. Loss cf Energy
00 I have as much energy as ever.
10 I have Iess energy than I used to have.
20 I dont have enough energy to do very much.
3D I dont have enough energy to do anything.
16. Changes in Sleeping Pattern
00 I have not experienced any change in my sleeping pattern.
10 I sieep somewhat more than usuai.
10 I sleep somewhat iess than usual
20 I sIeep a lot more than usuai.
20 I sieep a lot Iess then usuai.
3D I sleep most of the day.
30 I wake up 1-2 hours earIy and can’t get back to sleep.
17. Irritability
00 I am no more irritable than usual.
10 I am more irritable than usual.
20 I am much more irritable than usual.
3D I am irritable ail the time.
18. Changes in Appetite
00 I have flot experienced an change
in my appetite.
10 My appetite s somewhat iess than usual.
10 My appetite s somewhat greater than usual.
20 My appetite s much Iess than before.
20 My appetite is much greater than usual.
3D I have no appetite at aIl.
30 I crave food ail the time.
19. Concentration Difficulty
00 I can concentrate as weII as ever.
10 I cant concentrate as weII as usual.
20 Its hard to keep my mmd on anything
for very long.
3D I find I cant concentrate on anything.
20. Tiredness or Fatigue
00 I am no more tired or fatigued than usual.
10 I get more tired or fatigued more easily
than usual.
20 I am too tired or fatigued to do a lot of the
things I used to do.
3D I am too tired or fatigued to do most of the
things I used to do.
21. Loss of lnterest in Sex
00 I have not noticed any recent change in my
interest in sex.
10 I am Iess interested in sex than I used to be.
20 I am much Iess interested in sex now.
30 I have Iost interest in sex completely.
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Have you experienced any cf the following? Neyer For 2 or more In past 2 In past
weeks in past weeks week
(place check marks in ail boxes that apply) 6 months
1. stiffness
2. cravings
3. nausea or vomiting
4. muscle weakness
5. poor appetite
6. heartburn
7. muscle pain
8. numbness and/or tingling
9. constipation
10. severe cramps
11. chills
12. enlarged glands
13. difficulty geffing te sleep
14. dizziness
15. enlarged Iymph noUes
16. headache
17. low libido
18. body change
19. poor quality of sleep
20. difficulty with concentration
21. forgeffulness
If you experienced any of the above in the the past 6 months:
How much did it affect your day-to-day functioning? flot at alla somewhatD a great dealO
How much did it reduce your quality cf life? flot at alIC somewhatD a great dealo
1. Anti-HIV agents (e.g., AZT1, 3TC, d4T, ddi, crixivan, ritonavir, saquinavir etc.)...
flot at ail somewhat very confident
confident confident
Prolong Life
Prevent Symptoms
Boost lmmunity
Complement Other Agents
Improve Functioning
Increase Weii-Being
2. Preventative Medications (e.g. Septra,dapsone,pentamidine,etc.) for infections like CMV,PCP, etc.
flot at ail somewhat very confident
confident confident
Prolong Life
Prevent Symptoms
Boost immunlty
Compiement Other Agents
improve Functioning
increase WeiI-Being
3. Alternative Treatments (e.g., herbai medicines, high dose vitamins, etc.)
flot at ail somewhat very confident
confident confident
Prolong Life
Prevent Symptoms
Boost immunlty
Complement Other Agents
improve Functioning
Increase WeliB&nçj
[4. Nutritional Supplements (e.g., Boost, Ensure, etc.)
flot at ail somewhat very confident
confident confident
Prolong Ufe
Prevent Symptoms
Boost Immunity
Complement Other Agents
Improve Functioning
Increase Weii-Being
Please check the box (I) that best describes how confident you are of receiving these benefits
from the medications you are taking:
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Specifically regarding HAART medications, how MUCH bnefft
are you receiving, or expect to receive from these medications
(please check Vone answer only for each item)
None A Little Some A Lot
1. Increase in energy levels andlor appetite
2. General well-being
3. Restored libidolsex drive
4. Increase your capacity to perform daily
activities
5. Increase the likelihood of returning to part-time
or fuil-time work
6. Increase in CD4 ceil count
7. Decrease in viral load
How much do you feel these medications are NEAIIVEIX affecting
the following:
(please check ifone answer only for each item)
Strongiy Moderately Mildly No Effect
1. Ihe amount of time you spent on work or
other activities
2. Your ability to accomplish what you want
in your regular daily activities
3. The kind of work or activities you would
like to do
4. Your ability to work at a job or go to school
5. Your ability to work around your home
(e.g.,_cooking,_cleaning)
6. Your ability to care for yourself
7. Your social activities (like visiting with
friends or close relatives)
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People may miss taking their medications for various reasons. Here is
a list of possible reasons why you may have missed taking your
medications in the past week.
How oflen have you missed taking Place a checkmark afin the appropriate box
your medications because you:
Neyer Rarely Sometimes Often
Slept in late OR went to bed early
Feu asleep and slept through dose
time
Busy with other things
Lost track of time
Forgot
Could flot find a place where no one
would see you taking medicines
Was having problems with side
effects
Didnt want to take them
Had a change in daîly routine
Was traveling or away from home
Wasn’t feeling well
Feit too tired
FeIt depressed
FeIt stressed out
Could not follow eating pattern
required by medication
Had too many puIs to take
FeIt like the drug was toxic or harmful
to health
Ran out of puis
FeIt good
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Vhat do vou fmd parncuariv heipfu1 ifl vour life that heïps ou adhere to the
HAART medication? That is. things vou do for vourseif. things you teil
vourseÏf. objects that you value, techniques that you find usefiul. people in vour
life. etc. Please describe.
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NO YES morth year
1. Premature weight, i.e., more than 4 weeks
.. Weight less than 5 pounds
3. Mother had difficuit pregnancy
4. Sirth complications
5. Special observation due to medical problems at birth
6. Major illness before 6 yrs
7. Seizures 2nd to fevers before 6 years
NO YES month year
8. Learning difficulties in school
9. Attended speech therapy in school
10. Required special education classes or tutoring
11. Diagnosed with a learning disability
12. Diagnosed with Dyslexia
13. Diagnosed with ADHD
14. Held back a grade in school
NO YES month year
15. 15t head injury with unconsciousness
Length of loss of consciousness for 1’ head injury(in mins)
Days hospitalized for 1’ head injury
Number of days amnesic with 1 head injury
Residual neurological symptoms with lst head injury YesD NoD
.. NO YES month year
16. 2 head injury with unconsciousness
Length of loss of consciousness for l head injury(in mins)
Days hospitalized for lst head injury
Number of days amnesic with 1 head injury
Residual neurological symptoms with 1t head injury YesD NoD
NO YES month year
t NCOND2d#
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17. Additional head injuries (>2) with complications
NO YES month year
18. Evaluated by neurologist or neurosurgeon
19. Estimated numberofseizures
20. History of epilepsy
21. History of meningitis
22. History of encephalitis
23. History of migraines or severe headaches
NO YES month year
24. Given EEG
25. Given MRI scan
26. Given CT scan
27. Given other brain test (see code)
28. Previous cognitive/NP testing
NO YES month year
29. Alcohol blackouts
30. Seizures secondary to ethanol or drugs
31. Unconscious due to drug overdose
32. Unconscious due to ethanol overdose
33. Received general anesthesia
34. Loss of consciousness because of Iack of oxygen
35. Loss of consciousness because of toxic fumes
36. Received CPR
NO YES month year
37. High blood pressure (>140/90)
38. History of coronary artery disease
39. Currently elevated liver function tests
40. History ot elevated liver function tests elevated
41. Diagnosis of hepatitis A
42. Diagnosis of hepatitis B {
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43. Diagnosis of hepatitis C
44. DIagnoss 0f cirrhosis
NO YES month year
45. History of kidney disease or complications
46. History of thyroid complications
47. Chronic lung disease (e.g., COPD)
48. Diagnosis of asthma
49. Anemia/chronic blood disease
50. Diagnosis of Type I diabetes
51. Diagnosis of Type il diabetes
52. Other metabolic disease
NO YES month year
53. Elevated cholesterol or triglycerides
54. Diagnosis of llpodystrophy
55. Diagnosis of arthritïs
56. Current neuropathy in hands
57. Current neuropathy in feet
58. History of neuropathy (not current)
59. Diagnosis of cancer
60. Number of overnight hospitalizations
61. Other medical condition____________________________
62. Other medical condition
No In past 6 In past More than a
neyer months year year ago
1. Received psychiatric and/or psychologic help
2. Diagnosed as having a psychiatric condition
describe________________________________________________________
2. Hospitalization for psychiatric condition
describe_____________________________________________________
3. Medication for psychiatric condition
describe_____________________________________________________
n
-- NCOND4
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4. Other treatment for psychiatric condition:
describe_____________________________________________________
5. Psychotherapy or counseling t
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Please review the iNnesses isted below and if you have ever I Date when ast occurred
experienced any cf these, provide the date when ast experienced
(specify approximate month and year only)
1. Pelvic nflammatory Disease (PID) Month_____ Year
2. Cniptosøoria Month______ Vear
3. Salmoneila septicemia Month______ Year
4. Hawv Leukoplakia, oral Month______ Year
5. Tubercuiosis (TB) Month______ Year
6. Cytomegalovirus (CMV) Month______ Year
7. Kaooss Sarcoma Month_____ Year
8. Cervical Dvsplasia Month_____ Year
9. Histoplasmosis Month______ Year
10. Toxoplasmosis Month_____ Year
1 1. Lymphoma Month_____ Year
12. Coccidioidomycosis Month Year__
13. Pneumonia (PCP) Month_____ Year
14. Folliculitis Month_____ Year
15. Progressive Multifocal Leukoencephalopathv (PML) Month_____
16. Encephelolopathy Month Year___
17. Shingles (zoster) involving at least two distinct episodes Month Year__
18. Isosporiasis Month_____ Year
19. Mycobacterium Avium Intracellulare (MAI) or Complex (MAC) Month_____ Year__
20. Peripheral Neuropathy Month_____ Year
21. Constitutional symptcms (fever 38.5°C or more; diarrhea) for more than 1 month Month_____ Year
22. diopathic Thrombocvtopenic Purpura Month______ Year
23. Listehosis Month______ Year
24. Bacillary Angiomatosis Month______ Year
25. Candidiasis, vulvovaginal Month______
26. Month_____ Year
27. Month_____ Year
28. Month_____ Year
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Hospitahzations in past 6 months:
J When?________________ Duration___________ Reason____________________________________________
2. Nhen?_______________ Duration__________ Reason_________________________________________
3. When?_______________ Duration__________ Reason_________________________________________
4. ‘Nhen? Duration Reason_________________________________________
What hand do you use for writing? RightE Left Both right and Ieft
Race: BIack Caucasiani Asian South Asian North-American AboriginaI HispanicE Other__________
Date ficst tested HIV positive (dcl MMM yyyy)
___
___
___
___
___
Risk factor(s) for H!V (mark aU that apply)
heterosexual sexual contactiD same sex sexual contact/MSWMD blood transfusionD ntrveiiS dr
ug useC
other_____________________________
Please mark (f) the answer that is correct for you.
Two ta four Twa ta three Four or more
1. How often do you have a drink Neyer or Iess Monthly times a month times a week times a week
containing alcohol? E E E
2. How many drinks containing none 1 or 2 3 or 4 5 or 6 7 or 9 10 or more
alcohol do you have ona t]J E E E E
day when you are drinking?
3. How many drinks containing none 1-4 5-8 9-12 13-15 16 or more
alcoholdoyouhaveonaypjj E E E E E E
Less than Daily or
4. How ofien do you have Neyer monthly Monthly Weekly almost daily
mr drinks on one occasion? E E E E E
5. How often during the Less than Daily or
have you found that you were Neyer monthly Monthly Weekly almost daily
not able to stop drinking once E E E E Eyou had started?
6. How often during the Less than Daily or
have you failed to do what was Neyer monthly Monthly Weekly almost daily
normally expected from you E E E E Ebecause of drinking?
7. How often during the IaLr Less than DaUy or
have you needed a flrst drink in Neyer monthly Monthly Weekly almost daily
the moming ta get yourself going E E E E D
after a heavy drinking session?
8. How often during the last vear Less than Daily or
have you had a feeling of guilt or Neyer monthly Monthly Weekly almost daily
remorse after dnnking? E E E E E
9. How often during the 1t.i
have you been unable to Less than Daily or
remember what happened the Neyer monthly Monthly Weekly almost daily
nighibeforebecauseyouhad E E E E E
10. Have you or someone else Yes, but not in Yes, dunng
been injured as a resuit of your No the last year the last year
dnnking? E D E
11. Has a relative or friend, or a
doctor or other health worker Yes, but not in Yes, during
been concemed about your No the last year the last year
drinking or suggested you cut D E D
down?
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Have you ever smoked stiil smol’ingD
tobacco? neyer0 started at age or quit 2t age
The following questions concern information about your potential involvement with drugs exciuding alcohol and tobacco
during the oast 12 months. Carefully read each statement and decide if your answer s No’ or “Yes’. Then, check (J) the
appropriate box beside the question.
The phrase “recreational drugs” means any non-medical use of drugs and the use of prescribed or over-the-counter
drugs in excess of the directions. The various classes of drugs may include: cannabis (e.g., marijuana, hash),
tranquilizers (e.g., Valium), barbiturates, cocaine, stimulants (e.g. speed), hallucinogens (e.g., LSD) or narcotics (e.g.,
codeine or heroin) or solvents. Remember that the following questions QnQ indude alcohol or tobacco.
No Yes
1. Have you used drugs other than those required for medical reasons?
2. Have you used prescription drugs in excess cf directions?
3. Do you use more than one recreational drug at a time?
4. Can you get through the week without using recreational drugs?
5. Are you aiways able to stop using recreational drugs when you want ta?
6. Have you had “blackouts” or Uflashbacks as a resuit cf recreational drug use?
7. Do you ever feel bad or guilty about your recreational drug use?
8. Does your partner/spouse (or parents) ever complain about your involvement with dmgs?
9. Has the use of dwgs created problems with your padner/spouse or your parents?
10. Have you lost friends because of your recreational drug use?
1 1. Have you neglected your family because of your use of recreational dmgs?
12. Have you been in trouble at work because of your use of recreational drugs?
13. Have you lost a job because cf your use cf recreational drugs?
14. Haye you gotten into fights when uEder the nfluence cf recreational drugs?
15. Have you engaged in illegal activities in order to obtain recreational drugs?
16. Have you been arrested for possession of illegal drugs?
17. Have you ever experienced withdrawal symptoms (feit sick) when you
stopped taking recreaticnal drugs?
18. Have you had medical problems as a resuit cf your recreational drug use
(e.g.,_memory loss, hepatitis, convulsions, bleeding, etc.)?
19. Have you gone to anyone for help for a drug problem?
20. Have you been involved in a treatment program specifically related to
recreational drug use?
Annex B: Consent forms
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GENFRAL INFORMATION
INFORMM-HAART Study
(Identification of Necessary Factors for Medication Management of HAART)
The INFORMM-HAART Study focuses on identifying key things that might affect a persons ability
to stnctly follow antiretroviral medication directions as prescribed. The reason why this is important is that
if we can identify specific things that are associated with helping people better manage their medications
effectively, then we can help to maximize the therapeutic effectiveness of the medications (i.e., in reducing
plasma viral load or to maximize CD4 Lymphocyte counts).
lii this study, we will be recruiting and following over 9 months 250 individuals with H1V-infection on
highly active antiretroviral therapy (HAÀRT) or triple-dmg antiretroviral therapy.
Here are the essential requirements of the study:
We will ask you to corne in to the study office to complete questionnaires and cognitive tests at various
intervais across the 9 months of the study. You will be asked to complete (a) 3-hour assessment during the
1 and 9h month of the study and (b) 1-hour assessments during the 3rd and 6ih month of the study. For
the 3-hour assessments, you will receive $ 50.00, and $ 20.00 for the 1-hour assessments.
Over the course of the 9 months of the study, we will ask you to complete weekly medication checklists
that take about 5-10 minutes to complete. We will ask you to keep track of these ratings and we wilI ask
that every month we go over these ratings with you at least twice (i.e., once eveiy 2 weeks). We would
like for you to come in to the study office for at least one of these 2 monitoring sessions, but the other can
be done by phone. These sessions will take 15-30 minutes and you will receive $10.00 for each one
completed. if it does flot interfere with your regular rnedication schedule, we may ask you to use an
electronic piil bottie for one of your medications. This electronic pili bottie bas a microchip in its cap that
keeps track of when you open and close your medication bottle. If you agree to use it, we would have you
bring in it every two weeks (which would coincide with your bi-weekly medication monitoring session) so
that we can download the information into a computer.
Ail sessions will be arranged at times that are convenient for you any time Monday thru Friday from 8:00
am until 7:00 pm.
The interviews, tests, and questionnaires that you will receive during the course of study involve no
specific risks or discomforts beyond that of a standard clinical interview situation.
We will ask you for permission to contact your primary care physician w get confirmation of your HW
status and also to collect regular blood resuits (e.g., CD4, viral Ioad, etc). We are asldng your permission
to do this so that we do flot have to ask you to have any additional blood draws.
There is certain information that is collected as part of this study that you may want for us to communicate
to your primary care physician or specialist and we would be g]ad ta do this with your consent. Related to
this, there may be information collected as part of this study that you may flot want your primary care
physician or specialist to know about. Because this is a confidential study, it is important that you know
that of the information that is collected as part of this swdy can be released without your permission.
You may refuse or stop participation in this study at any time without affecting you current andlor future
care at St. Michael’s Hospital (The Wellesley Central andlor Bond Street Sites).
Finally, you may be asked to participate in the MAX-HAART Study but a separate consent form will be
presented to you for this study; this witÏ occur after at Ïeast one month of monitoring in the TNFORMM
Study.
Consent to Act as a Research Participant
Study Titie
HAART ADHERENCE IN 111V-INFECTION PROJECT:
INFORMM-HAART Study
(Identification of Necessary factors for Medication Management of HAART)
PRINcIPAL INVESTIGATORS
Sean B. Rourke, Ph.D.’
St. Michael’s Hospital Mental Health Service and HIV Psychiatry Program
(416) 926-5053, extension 3737 (Monday to friday: 9:00 am - 5:00 pm)
William Lancee, Ph.D.’
Mount Sinai Hospital
(4 16) 586-4567 (Monday to Friday: 9:00 am - 5:00 pm)
Douglas Saunders, Ph.D.’
Department of Public Health Sciences, Univers ity of Toronto
(416) 597-0015
Co- IN VESTIGATORS
Ahmed M. Bayoumi’2, MD, MSc
Michelle Foisy’2, PharmD
Richard Glazier’2, MD, MPH
Mark H. Halman’2, MD
Colin M. Kovacs’, MD
Anita R. Rachlis’5. MD
Irving Salit’3, MD
William Seidelman’2, MD
Alice Tseng’3, PharmD
Sharon Walmsley’3, MD
Jiahui Wong’3, MD, MSc
An Zaretsky’4, MD
‘University ofloronto, 2St. Michael’s Hospital, 3Toronto Hospital (General Division),
4Mount Sinai Hospital, ‘Sunnybrook Health Sciences Centre
Study Sponsor
Ontarlo Ministry of Health AIDS Bureau (Positive Action Fund)
Before agreeing to participate in titis research study, it is important that you read and understand
this researcli consent form. This form provides ail the information we think you will need to know
in order to decide whether you wish to participate in the study. 1f you have any questions aftet you
read through this form, ask your questions to a doctor or study personnel. You should flot sign
this form until you are sure that you understand everything on this form. You may also wish to
discuss your participation in this study with your family doctor or close friend. It is important that
you are completely truthful with your study doctor with respect to your health history and any
medications you may be taking, in order to prevent any unnecessary harms to you should you
decide to participate in this study.
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Consent to Act as a Research Participant
Purpose of the Research Project
We are conducting a Project in HIV-infection that involves 2 distinct but Iinked swdies, each
with its own consent form:
(I) The INFORMM-HAART Study
(2) The MAX-HAART SWdy
The INFORMM-HAART Study is a natural history study that focuses on identifying
factors that are associated with managing antiretroviral medication regimens for the treatment of
HIV-infection. For this study, we will be recruiting and following over 9 months 250
individuals with HW-infection on highly active antiretroviral therapy (HAART) or triple-dmg
antiretroviral therapy.
The MAX-HAART Study is an intervention study that will compare the efficacy of three
different behavioural interventions to help HW-infected individuals achieve maximal HAART
adherence. If I agree to participate in the MAX-HAART Study (and sign a separate consent
form), I will be randomly assigned to receive one of these three interventions. Two of the three
interventions were chosen because there is preliminaiy evidence to suggest that they may be
beneficial in helping people keep to the schedule of their HAART medication regimen. By
doing this, the expectation is that stricter adherence to HAART regimen will lead to maximum
viral load response and minimal development of dmg resistance to HW. The third intervention
is a placebo’ or control condition where participants will receive an education-focused
intervention that is designed to increase knowledge of HAART agents and the behavioural
causes of adherence difficulties to help maximize HAART adherence.
Through the identification of individual risk factors for HAART adherence problems and with
behavioural interventions to improve HAART adherence, we expect that the resuits from this
Project will help to optimize climcal care and to maximize the health and vitality of HIV
infected individuals.
II. Procedure
The following consent is specifically for the INFORMM-HAART Study
If I agree to participate in this study, I will be asked to do the following:
(1) At study enrol]ment and completion (i.e., 9 months later), I will be asked to complete a
3-hour assessment that will include:
ta) Standardized neuropsychological tests (generally paper and pencil-type tasks) to
quantify my attention, thinldng skills, memoiy and motor functioning. These tests
may take up to 2 hours to complete.
(b) I will be asked to f111 out several questionnaires about my mood, coping style,
support system, health, and about any medicai or cognitive complaints that I may
have. These questionnaires may take up to I hour to complete.
I will receive $ 20.00 for each 3-hour assessment visit I complete. This will help to cover
transportation and other incidentai costs.
(2) Minor assessment sessions (i.e., 1-hour sessions) will take place at 1, 3 and 6 months. This
wilÏ include 20 minutes of standardized neuropsychologicai tests and up to 40 minutes of
questionnaires. Both the neuropsychological and questionnaires are similar to those given at
study enrollment and study completion (i.e., 9 months). I wilI receive $ 10.00 for each minor
assessment visit I complete. This is to help cover transportation and other incidentai costs.
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Consent to Act as a Research Participant
(3) My HAART medication adherence wili be monitored over a 9-month period using both self-
report adherence questionnaires and an electronic drug exposure monitoring device (eDEM).
The eDEM is an electronic pili bottie that I will be asked to use to hold one of my HAART
medications. The eDEM will keep track of each tirne that I open the bottie to take one of my
HAART medications at the prescribed time.
I understand that I will be required to corne in to the laboratory at the following intervals so
that my HAART adherence can be monitored:
• Weekly for the first month of the study
• A minimum 1-2 times per month (depending upon my schedule) for months 2 and 3 of
the study
• For the last 6 months of the INFORMIVI-HAART Study, I will be required to corne in
once per month
I will receive $ 10.00 for each monitoring visit. This is to help cover transportation and other
incidentai costs.
(4) I understand that my HW infection will need to be documented by consultation with my
primary care/family physician, who wïli have records of HIV infection through either ELISA
antibody testing or positive viral load testing by PCR technique. I also understand that it will
be helpful to obtain my current and past blood test resuits, including CD4 Lymphocyte
counts, viral load counts, liver function test resuits, and general blood chemistry resuits
(e.g., hemoglobin, glucose, cholesterol, etc.) from my primary care/family physician. I
understand that the investigators will need to contact my pnmary care physician in order to
obtain this documentation and they have my permission to do so.
(5) 1 understand that Dr. Rourke, or his associates, will answer any questions that I may have at
any time conceming the details of the procedures performed as part of this study. I
understand that I may also contact Dr. Rourke at 926-5053, ext. 3737 at a later time, if I have
any questions conceming this study.
(6) If I am interested, Dr. Rourke can give me feedback on my test results at any time. Also, if it
would be helpful for my medical treatment, Dr. Rourke can arrange to communïcate pertinent
test results to my primary care physician or health care professionai, but only with my
informed consent and written permission (signed form 14).
(7) I understand that I may refuse or stop participation in the study at any time without affecting
my current andlor future care at St. Michael’s Hospital (The Wellesley Centrai andlor Bond
Street Sites).
(8) I understand that at the end of the 9 months, I may be asked to participate in a follow-up
study. If so, a separate consent forrn will be presented to me at that time. I may choose flot to
participate further.
(9) 1 understand that I may be asked to participate in the MAX-HAART Study to help improve
my ability to follow my HAART medications. A separate consent form will be presented to
me at that time; this wiIl occur after at Ieast one month of monitoring in the INFORMM
Study. However, my refusai to participate in the MAX-HAART Study wilI flot hinder my
participation in the INfORMM-HAART Study.
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III. Benefits
There are two main benefits in participating in this research study:
(1) Dr. Rourke can meet with me to give me feedback on my test resuits over the study
period. In addition, if I am interested, Dr. Rourke can also arrange to communicate these
findings to my primaly care physician or other clinicians involved in my medical care
with my informed consent and written permission (Form 14).
(2) My participation in the INFORIvIM-HAART Study is helping to ascertain the essential
factors that are associated with maximizing HAART medication adherence. I understand
that while this will flot directly help me at the present time, it will be helping to collect
information and knowledge in this area and might help others with HW4nfection in the
future.
IV. Discomforts and Risks
The interviews, tests, and questionnaires that I will receive during the course of study
involve no specific risks or discomforts beyond that of a standard clinical interview situation,
such as feeling upset at a review of my medical or mental health status, or a feeling of
boredom or fatigue. Although most researcli participants and patients have found the
experience of neuropsychological testing to be beneficial in the management of their I-11V
disease, a small minority of patients find it upsetting to participate in these tasks, as they find
out that their cognitive skills (e.g. their memory or concentration skills or problem-solving
ability) are below what they expected.
V. Confidentialitv and Privacy
Confidentiality will be respected and no information that discloses my identity will be
released without my consent, unless required by law. I will be given a research number and
my personal identity will flot be revealed on any forms, questionnaires, or in any
publications.
VI. Compensation for Injurv
If I suffer a physical injuly as a direct resuit of the administration of study procedures,
medical care may be obtained in the same manner as I would ordinarily obtain any other
medical treatment. In no way does signing this form waive my legal rights nor relieve the
investigators, sponsors, or involved institutions from their legal and professional
responsibility.
VII. Participation and Withdrawal
Participation in research is voluntary. If I choose flot to participate, I will continue to have
access to customaiy care at St. Michael’s Hospital (Weflesley Central and Bond Street Sites).
If I choose to participate in this study, I can withdraw from the study at any time without any
affect on the care that I will receive at St. Michael’s Hospital (Wellesley Central and Bond
Street Sites).
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VIII. Consent
I acknowledge that the research study descnbed above lias been explained to me and that any
questions that I have asked have been answered to my satisfaction. I have been informed of
the alternatives to participation in this study, including the right not to participate and the right
to withdraw without compromising the quality of medical care at St. Michael’s Hospital for
me and for other members of my family. As welI, the potential risks, harms and discomforts
have been explained to me and I also understand the benefits of participating in this research
study.
I understand that I have flot waived my legal rights nor released the investigators, sponsors,
or involved institutions from their legal and professional duties. I know that I may ask now,
or in the future, any questions I have about the study or the research procedures.
I have been assured that records relating to me and my care will be kept confidential and that
no information will be released or printed that would disclose personal identity without my
permission unless required by law. I have been given sufficient time to read and understand
the above information.
If I have any questions or concems about this study, I may contact Dr. mue Spence the Chair
ofthe St. Michael’s Hospital Research Ethics Board at (416) 864-6060, ext 2557.
By signing this document, I am giving my informed consent to participate in this study. I
have also been given a copy of this consent form.
Participant signature Pnnt Name Date
I, the undersigned, have fully explained the relevant details of thïs study to the patient named above
and believe that he/she understands the nature of the study.
Person obtaining consent Pnnt Name Date
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